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Abstract 
UDP-glucuronosyltransferases (UGTs) are a family of metabolic enzymes responsible for 
the detoxification of a wide range of endo- and xenobiotics, including drugs. UGT-
mediated metabolism is a major determinant of the pharmacokinetic behavior of many 
drugs in the human body, contributing to parameters such as bioavailability and 
elimination. UGTs catalyze the transfer of glucuronic acid from UDP-glucuronic acid 
(UDPGA) to the aglycone substrates, producing water-soluble glucuronide conjugates that 
are mostly devoid of pharmacological activity. Some of the 19 human UGTs have the 
ability to conjugate different nitrogen-containing compounds, thus forming N-
glucuronides. N-Glucuronidation exhibits marked differences across species. As an 
example, the ability to form quaternary ammonium glucuronides from tertiary amines is a 
reaction largely, but not completely, restricted to humans. Among the human UGTs, 
UGT1A4 has been considered the enzyme “specializing” in N-glucuronidation.  
The goal of this study was to characterize species differences related to N-
glucuronidation and to elucidate whether human UGT enzymes other than the previously 
reported UGT1A4 catalyze this reaction. The nitrogen-containing substrates investigated 
were firstly a set of 4-arylalkyl-1H-imidazoles, including the sedative drug 
dexmedetomidine [(+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole], and secondly 
nicotine, the addictive agent in tobacco products, along with its major metabolite cotinine. 
The study was performed using different in vitro systems, such as human and animal liver 
microsomes and recombinant human UGT enzymes produced in baculovirus-infected 
insect cells. The 4-arylalkyl-1H-imidazole substrates were incubated with a radiolabeled 
cofactor, 14C-UDPGA, and the glucuronide products were analyzed by liquid 
chromatography using ultraviolet detection combined with a flow scintillation analyzer. 
Nicotine and cotinine glucuronides were quantified using liquid chromatography – mass 
spectrometry.  
Analyses of liver microsome incubates indicated that N-glucuronidation of 
medetomidine was efficient in humans, while the glucuronidation rates measured in rat, 
mouse, guinea-pig, rabbit, dog, mini-pig, and monkey liver microsomes were rather low. 
Studies with recombinant human UGTs revealed that the “orphan enzyme” UGT2B10, 
which has previously demonstrated no or only very limited activity when screened against 
a large variety of substrates, plays an important role in the N-glucuronidation of the 
compounds investigated. More specifically, we discovered that UGT2B10 is the enzyme 
mainly responsible for nicotine N-glucuronidation in the human liver, and, furthermore, 
this enzyme is a major contributor to the N-glucuronidation of medetomidine.  
Nuclear magnetic resonance (NMR) analyses revealed that the N-glucuronidation of 
medetomidine by human liver microsomes was highly regioselective, and that N3 was the 
preferred site of glucuronidation. Moreover, this chiral drug was N-glucuronidated 
stereoselectively. Regio- and stereospecific N-glucuronidation of medetomidine in human 
liver microsomes was explained by complex kinetics involving two enzymes, UGT1A4 
and UGT2B10. UGT2B10 was found to be a high-affinity (low Km) enzyme towards 
medetomidine, while the affinity of UGT1A4 was considerably lower. Levomedetomidine 
 
 
 
 
[(–)-4-(R)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole], in particular, turned out be a 
high-affinity, specific substrate of UGT2B10.  
The results emphasize the species differences of N-glucuronidation and the importance 
of in vitro studies utilizing human-derived material, along with animal studies, at the early 
stages of drug development. Furthermore, this study highlights the contribution of 
UGT2B10, along with UGT1A4, to the N-glucuronidation of drugs and other xenobiotics 
in the human liver. 
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1. Introduction 
The ultimate goal of drug development is to produce safe and efficacious drugs. 
Elucidating the ADME properties (absorption, distribution, metabolism, excretion) of a 
new drug candidate is a crucial part of the drug development process contributing to both 
of these objectives (Lin et al., 2003; Singh, 2006). With respect to pharmacological 
activity, reaching the pharmacological target, such as a receptor, is a prerequisite for drug 
action, and ADME properties determine the fate of the drug in the human body. When 
given orally, the drug molecules are first released from the formulation, and only the 
portion that is dissolved in the intestinal fluids can be absorbed (Fig. 1). During the 
absorption phase, the drug permeates the cellular membranes of the intestinal wall and 
enters the portal vein. Enterocytes at the intestinal wall contain specific efflux proteins 
regulating the rate of absorption. Before reaching systemic circulation, the drug enters the 
liver and is subjected to metabolism. Metabolism is catalyzed by a wide variety of 
metabolic enzymes converting drugs to generally more water-soluble products, 
metabolites. The metabolites formed are usually devoid of pharmacological activity, 
suggesting that metabolism often ends drug action. On the other hand, some drugs (called 
“prodrugs”) need metabolic activation to produce the pharmacologically active agent. The 
fraction absorbed and the rate of hepatic and intestinal “first-pass metabolism” together 
dictate bioavailability, i.e. the relative proportion of the drug entering systemic circulation. 
After reaching systemic circulation, the drug can be distributed further to tissues, 
including the site of action in the target tissue. The elimination phase of the 
pharmacokinetic process dictates the duration of drug action. Drugs can be excreted to 
urine or bile as such, but in most cases they are excreted as metabolites. The hydrophilic 
moieties introduced to the drug molecules by metabolic enzymes facilitate excretion, and, 
moreover, many metabolites are substrates of specific transport proteins controlling their 
excretion in the liver and kidney.  
With respect to the safety aspect of drugs, ADME plays a role in some undesired drug 
responses. Some metabolic enzymes convert drugs into reactive intermediates that can be 
covalently bound to proteins and nucleic acids (Nassar and Lopez-Anaya, 2004; Zhou et 
al., 2005b). This metabolic activation has, in some cases, been shown to be related to toxic 
responses, such as organ toxicity or idiosyncrasies. Furthermore, some drugs have the 
potential to inhibit metabolic enzymes, thus increasing the exposure to other drugs taken 
concomitantly. Many clinically relevant drug-drug interactions are related to cytochrome 
P450 enzymes (CYPs) (Pelkonen et al., 2008), as a variety of drugs are metabolized by 
these enzymes. In addition, genetic variation in metabolic enzymes can cause large 
interindividual variability in drug levels, since the polymorphic variants may catalyze 
metabolism at highly different rates (Ingelman-Sundberg et al., 2007). CYP enzymes 
appear to be mostly responsible for the clinically relevant drug-drug interactions, drug-
related toxicities, and interindividual variation in drug response reported thus far. The 
possibility for such reactions is therefore evaluated early in the drug discovery process. 
Furthermore, some drug companies may even try to focus on developing drugs that are 
preferentially eliminated via other enzymes than CYPs.  
 Figure 1 ADME (absorption, distribution, metabolism, excretion) process of an oral drug. 
In the past, poor pharmacokinetics and metabolic properties have been among the most 
important reasons for the failure of a new drug in development (Kennedy, 1997; Roberts, 
2003). As a result, ADME studies are nowadays initiated at a very early stage during the 
drug discovery process to ensure that the new drug candidates will not fail due to poor 
ADME properties. In fact, many in vitro approaches for drug metabolism and interaction 
studies have emerged to complement and in some cases even replace laborous in vivo 
studies. These in vitro methods are routinely used in the early testing of drug metabolism 
and enable the rapid screening of a large set of drug candidates in a single test. The first in 
vitro screens usually include CYP inhibition screening as an indication of the interaction 
potential, and metabolic stability testing using human and animal liver microsomes 
(Brandon et al., 2003; Plant, 2004; Pelkonen and Raunio, 2005; Pelkonen and Turpeinen, 
2007). In vitro testing is beneficial also in terms of being able to use human-derived 
material already during the first steps of drug development, as large differences among 
species in metabolism have been reported, and interspecies extrapolations from animals to 
humans are often rather poor. 
This study was designed to explore N-glucuronidation, a specific metabolic reaction 
playing a central role in the elimination of many drugs and xenobiotics. Different in vitro 
approaches, including human and animal liver microsomes, and recombinant human UDP-
glucuronosyltransferase (UGT) enzymes were used to explore this reaction. A set of 
closely related 4-arylalkyl-1H-imidazoles and nicotine along with its major metabolite 
cotinine were used as test substances. Special emphasis was given to attempts to clarify 
the human UGTs contributing to this reaction in the human liver.  
12 
 
 
 
 
13 
 
 
 
 
2. Review of the literature 
2.1 Drug metabolism 
Drug metabolism refers to the biochemical modification of drugs by specialized enzymatic 
systems. Overall, the role of metabolism is to protect the body against potentially harmful 
chemicals, including drugs and other xenobiotics, such as enviromental chemicals and 
food additives. Metabolism converts these chemicals generally into less toxic and more 
polar products, metabolites, and is therefore referred to as a detoxification system.  
Drug metabolism is traditionally divided into two types of reactions, phase I 
(oxidation, reduction, and hydrolysis) and phase II (conjugations) (Guengerich, 2008; 
Remmel et al., 2008). The most common phase I and II reactions along with the enzymes 
catalyzing the reactions are presented in Table 1 (Ekins et al., 1999). As reviewed by 
Williams (2004a), approximately three-quarters of the top 200 prescribed drugs in the 
United States in 2002 were reported to be mainly cleared by metabolism. Whereas some 
drugs have one clearly dominant metabolic pathway, others have several equally important 
routes. The most important enzymes catalyzing phase I drug metabolism are CYPs, 
contributing to the clearance of two-thirds of drugs cleared by metabolism. Furthermore, 
many drugs are cleared predominantly by phase II reactions such as direct 
glucuronidation. In fact, glucuronidation, catalyzed by a family of UGT enzymes, was 
reported to contribute to the metabolism of approximately one-tenth of drugs (Williams et 
al., 2004a). In phase II reactions, an endogenous cofactor is conjugated to the drug or the 
newly formed phase I metabolite to form a conjugate that is usually highly polar.  
Liver is quantitatively the principal organ of drug metabolism. Nonetheless, most 
tissues, such as the intestine, kidney, lung, and skin, have some ability to metabolize 
drugs. Therefore, when a drug is taken orally, it is subjected to metabolism before entering 
systemic circulation first during the absorption phase in the epithelial cells of the 
gastroinstestinal (GI) tract, and again when entering the liver via the portal vein. This 
process, “first-pass metabolism”, is an important determinant of the bioavailability of 
many oral drugs.  
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Table 1 Characteristics of major drug metabolism enzymes (modified from Ekins et al, 
1999). 
Enzyme Abbreviation Reaction Cellular localization Cofactor
a 
Phase I enzymes     
Cytochrome P450s CYPs Oxidation or 
reduction 
Microsomal NADPH 
Flavin-containing 
monooxygenases 
FMOs Oxidation Microsomal NADPH 
Monoamine oxidases MAOs Oxidation Mitochondrial  
Alcohol- and aldehyde 
dehydrogenases 
ADHs,  
ALDHs 
Oxidation or 
reduction 
Cytosolic NAD+ 
Phase II enzymes     
UDP-glucuronosyltransferases UGTs Glucuronidation Microsomal UDPGA 
Sulfotransferases SULTs Sulfation Cytosolic PAPS 
Glutathione S-transferases GSTs Glutathione 
conjugation 
Cytosolic and 
microsomal 
Glutathione 
N-Acetyltransferases NATs N-Acetylation Cytosolic Acetyl-
coenzyme A 
Methyltransferases MTs Methylation Cytosolic S-Adenosyl-
methionine 
aAbbreviations of the cofactors: NADPH, β-nicotinamide adenine dinucleotide phosphate, reduced form; 
NAD+, β-nicotinamide adenine dinucleotide; PAPS, 3’-phosphoadenosine 5’-phosphosulfate 
2.2 Glucuronidation and the UDP-glucuronosyltransferase 
(UGT) enzyme system 
2.2.1 Overview 
Glucuronidation, catalyzed by a family of membrane-bound UGT enzymes (Burchell and 
Coughtrie, 1989; Miners and Mackenzie, 1991; Tukey and Strassburg, 2000; Wells et al., 
2004), is a metabolic reaction converting lipophilic xeno- and endobiotics to more water-
soluble metabolites, glucuronides. Substrates for UGT enzymes are compounds containing 
nucleophilic functional groups such as alcohols (ROH), phenols (Ar–OH), primary amines 
(RNH2), secondary amines (RNR’H), tertiary and heterocyclic amines (RNR’R’’), amides 
(R–CO–NH2), thiols (RSH), and acidic carbon atoms. The clearance of some endogenous 
substances, such as bilirubin, steroid hormones, and bile acids, is largely dependent of 
UGT-mediated metabolism. In addition, a large variety of drugs are metabolized primarily 
by glucuronidation. Examples of extensively O-glucuronidated phenolic drugs include 
opioids (codeine, morphine, naloxone), the anaesthetic propofol, the anti-Parkinson drug 
entacapone, and the contraceptive ethinylestradiol (Wikberg et al., 1993; Soars et al., 
15 
 
 
 
 
2002). Carboxylic acid drugs, which are excreted primarily by glucuronidation, include 
nonsteroidal anti-inflammatory drugs (ketoprofen, naproxen), the hyperlipidemia drug 
gemfibrozil, and the antiepileptic valproic acid (Soars et al., 2002). Readily N-
glucuronidated drugs include antihistamines, tricyclic antipsychotics, antidepressants, 
antiepileptics, and antipsychotics  (Dahl-Puustinen et al., 1989; Luo et al., 1991; Sinz and 
Remmel, 1991; Luo et al., 1995; Hawes, 1998; Kassahun et al., 1998).  
Formed glucuronide conjugates are generally polar, ionized at physiologic pH (pKa 
~4), and have an increase in molecular weight (+176) (Remmel et al., 2008). All of these 
features facilitate biliary and/or renal excretion. However, glucuronides are generally too 
large and too polar to diffuse passively to bile or urine, therefore needing specific 
transporters, such as multidrug resistance-associated proteins MRP2 and MRP3, to aid 
their movement across cell membranes (Zamek-Gliszczynski et al., 2006). In general, drug 
glucuronides are less toxic and potent than their aglycone substrates. However, in the case 
of the 6-O-glucuronide of morphine, the glucuronide product is in fact more potent than 
the parent drug, suggesting that this metabolite can increase the analgesic potency of 
morphine (King et al., 2000). In rare cases, glucuronidation reaction has been reported to 
produce reactive intermediates such as acylglucuronides (Sallustio et al., 2000; Bailey and 
Dickinson, 2003). Nonetheless, direct evidence for the toxicity of acylglucuronides is 
currently scarce. Clinically relevant polymorphisms related to UGT enzymes have been 
reported at least for the UGT1A1 enzyme (Miners et al., 2002). Therefore, to develop 
safer and more efficient drugs, it is important to recognize as early as possible whether 
glucuronidation is involved in the clearance of the new drug candidate, what types of 
glucuronides are formed and at what rate, whether significant species differences exist, 
and which human UGT isoforms are involved in the reaction. 
2.2.2 Glucuronidation reaction and cellular localization of the UGT enzyme 
UGTs catalyze the transfer of glucuronic acid from UDP-glucuronic acid to the aglycone 
substrate (Fig. 2). Glucuronidation occurs as an SN2 substitution reaction (Yin et al., 
1994). The nucleophilic heteroatom of the substrate attacks the C1 atom of the glucuronic 
acid, and both UDPGA and the aglycone substrate are bound on the active site of the 
enzyme. The SN2 mechanism is supported by the inversion of the α-configuration of the 
C1 atom in UDPGA to β-configuration in the glucuronide. 
Within the cell, the active site of the UGT enzyme is localized in the lumen of the 
endoplasmic reticulum (Fig. 3) (Banhegyi et al., 1993), whereas e.g. CYPs face the 
cytosolic side. Single UGT enzymes have been demonstrated to form di- and tetrameric 
structures, i.e. two or four either similar or different UGT enzymes form an oligomeric 
structure (Radominska-Pandya et al., 2005b; Finel and Kurkela, 2008). Whether these 
enzymes actually form such oligomeric structures within the ER membrane, and their 
functional relevance are not fully understood. 
 
OH
OH
H
O-UDP
H
OHH
OH
COO-
OH
NO2
O
NO2
OH
OH H
H
OHH
OH
COO-
+UDP
UGTs
p-Nitrophenol
UDP-glucuronic acid (UDPGA) p-Nitrophenyl-β−D-glucuronide  
Figure 2 Glucuronidation reaction. Conjugation of the aglycone substrate (p-nitrophenol) with 
glucuronic acid from UDPGA. The initial α-configuration of the glucuronic acid is 
converted to the β-configuration in the final glucuronide product.  
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Figure 3 Localization of the UGT enzyme in the ER membrane. UDPGA is transported into the 
ER and is trans-stimulated by UDP-N-acetylglucosamine (UDPGlcNAC). Modified 
from Clarke and Burchell (1994).  
While lipophilic xeno- and endobiotics can usually passively permeate through the ER 
membrane to access the active site of the enzyme, UDPGA is transported into the lumen 
of ER using active mechanisms (Bossuyt and Blanckaert, 1997). In the human liver, the 
concentration of UDPGA is 280 µM, while in extrahepatic tissues it is less than 20 µM 
(Lin and Wong, 2002). The physiological UDPGA concentrations in the cytosol and in the 
ER lumen were reported to be similar. The formed glucuronide conjugates generally need 
active transport through the ER membranes into the cytosol before they can be excreted 
out of the cell.  
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2.2.3 Heterogeneity and tissue localization of human UGTs  
The human genome contains some 19 active UGT-encoding genes, which are divided into 
three subfamilies: 1A, 2A, and 2B (Mackenzie et al., 2005). According to current 
understanding, two of these subfamilies, 1A and 2B, are mostly responsible for the 
glucuronidation of drugs and xenobiotics (Tukey and Strassburg, 2000; Mackenzie et al., 
2003; Ouzzine et al., 2003; Mackenzie et al., 2005). The human UGT1A enzyme family 
consists of nine members (UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, 
UGT1A8, UGT1A9, and UGT1A10). Each UGT1 enzyme is encoded by a transcript that 
is formed by the splicing of a distinct first exon, containing the code for the substrate 
binding region, to exons 2-5, a set of four common downstream exons that together 
contain the code for the UDPGA binding site (Mackenzie et al., 2003). The UGT2A 
family contains three members (UGT2A1, UGT2A2, and UGT2A3), while the UGT2B 
family contains seven members (UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, 
UGT2B17, and UGT2B28). The human UGT2A1 and UGT2A2 genes contain unique first 
exons (2A1 and 2A2) and a shared set of five downstream exons (Mackenzie et al., 2005). 
All other UGT2 enzymes are encoded by separate genes, each composed of six exons. 
The liver is generally considered the main drug glucuronidating organ in humans, and 
many UGT isoforms (1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B10, 2B11, 2B15, and 
2B17) are abundantly expressed in the liver (Table 2) (Nakamura et al., 2008). Ohno and 
Nakajin (2009) recently performed an extensive quantitative mRNA measurement of UGT 
expressions in 23 human tissue types. They reported that the hepatic expression was 
highest for four members of the UGT2B family, namely 2B4, 2B7, 2B10, and 2B15, while 
the expression levels of UGT1A enzymes were generally somewhat lower. 
Beyond the human liver, a wide variety of endo- and xenobiotics have been observed 
to be glucuronidated efficiently by microsomes isolated from other tissues, such as the 
intestine and kidney (Soars et al., 2002). Accordingly, many UGTs are expressed at 
considerable levels in extrahepatic tissues (Nakamura et al., 2008). The expression of 
UGT1A1, UGT1A10, UGT2B7, UGT2B15, and UGT2B17 was found to be particularly 
high along the intestine (Ohno and Nakajin, 2009). Also UGTs 1A7 and 1A8 are mainly 
expressed in the GI tract (Nakamura et al., 2008). Two UGT enzymes, UGT1A9 and 
UGT2B7, were expressed at particularly high levels in the kidney (Ohno and Nakajin, 
2009). Some UGTs are expressed also in steroid-related tissues (adrenal gland, breast, 
ovary, uterus, and testis) in a tissue- and isoform-specific manner, indicating their role in 
the glucuronidation of endogenous hormones (Nakamura et al., 2008). Of the UGT2A 
enzymes, UGT2A1 is an extrahepatic enzyme expressed mainly in the nasal epithelium 
(Jedlitschky et al., 1999), suggesting that it plays a minor role in drug metabolism. 
UGT2A3 mRNA, by contrast, is most highly expressed in human tissues of the greatest 
relevance to drug clearance, including the liver, GI tract, and kidney (Court et al., 2008). 
Taken together, these findings emphasize the role of several UGT2B family enzymes 
in the first-pass metabolism of oral drugs in both the GI tract and the liver. Moreover, 
these results indicate that UGT1A9 may play an important role in renal glucuronidation.  
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Table 2 Typical substrates of human UGTs and UGT expression in the body.  
Enzyme Probe substrates for 
hepatic UGTsa 
Other substrates Primary tissue(s) expressionb and 
other characteristics 
UGT1A1 Bilirubin 
Estradiol (3-O-gluc)c 
Small and bulky phenols Liver and GI tract 
Clinically relevant polymorphism 
UGT1A3 Hexafluoro-1α,25-
dihydroxyvitamin D3 
Small and bulky phenols 
Carboxylic acids 
Liver  
UGT1A4 Amitriptyline 
Trifluoperazine 
(TFP) 
 Liver  
Catalyzes N-glucuronidation  
Specific inhibitor hecogenind 
UGT1A5  Good substrates currently 
unknown 
Marginally expressed in many 
tissues, including the liver 
UGT1A6 Serotonin 
α-Naphthole 
Small, planar phenols Kidney and liver 
UGT1A7  Small and bulky phenols Esophagus 
Low expression in the liver 
UGT1A8  Small and bulky phenols 
 
Marginally expressed in many 
tissues  
Not expressed in the liver 
UGT1A9 Propofolc Small and bulky phenols 
Carboxylic acids 
Kidney and liver 
 
UGT1A10  Small and bulky phenols GI tract  
Not expressed in the liver 
UGT2B4  C19- and C21-steroids 
Hyodeoxycholic acid 
Liver and  heart  
 
UGT2B7 Carbamazepine 
Morphine  
Zidovudine 
Opioids, NSAIDs  
Carboxylic acids 
C19- and C21-steroids 
Hyodeoxycholic acid  
Liver, kidney, and GI tract 
Specific inhibitor fluconazole 
UGT2B10f Levomedetomidine Nicotine Liver  
Catalyzes N-glucuronidation 
UGT2B11  Good substrates currently 
unknown 
Marginally expressed in tissues 
UGT2B15 S-Oxazepam 
 
Androgens 
Testosterone 
Liver, GI tract, breast, and ovary 
UGT2B17  Androgens 
Testosterone 
GI tract 
 
UGT2B28  Good substrates currently 
unknown 
Marginally expressed in tissues 
aPotentially useful probe substrates for hepatic UGTs suggested by Burchell et al. (2005), Court (2005), and 
Miners et al. (2006).   
bPrimary sites of mRNA expression of each UGT enzyme according to Nakamura et al. (2008) and Ohno 
and Nakajin (2009). The major UGTs in the liver, kidney, and GI tract are indicated in boldface. 
cGlucuronidated also by extrahepatic UGTs 
dUchaipichat et al. (2006) 
eGlucuronidated also by other UGTs, but highest CLint observed with UGT1A6. 
f Role of UGT2B10 in N-glucuronidation is discussed in detail under Results and Discussion.  
2.2.4 Substrate specificity of human UGTs 
UGTs generally have distinct but broadly overlapping substrate specificities (Miners and 
Mackenzie, 1991). In other words, an individual UGT enzyme accepts multiple 
compounds as substrates, and a single compound is often a substrate for multiple UGT 
enzymes. Due to the overlapping substrate specificities, it has been a challenging task to 
try and find selective probe substrates for each UGT enzyme. Nonetheless, there are some 
“generally accepted” probe substrates and they are listed in Table 2 (Burchell et al., 2005; 
Court, 2005; Miners et al., 2006). UGT1A enzymes generally play a role in the O-
glucuronidation of planar and bulky phenols (Tukey and Strassburg, 2000). Moreover, 
UGT1A enzymes conjugate the endogenous substrate bilirubin and are involved in the N-
glucuronidation of various amines. UGT2B enzymes catalyze the O-glucuronidation of 
endo- and xenobiotic steroids and contribute to the conjugation of carboxylic acids such as 
many analgesic drugs.  
Williams et al. (2004a) and Burchell et al. (2005) have postulated that seven UGT 
enzymes, namely 1A1, 1A3, 1A4, 1A6, 1A9, 2B4, and 2B7, are mainly responsible for 
hepatic drug glucuronidation (Fig. 4). More specifically, UGT2B7 was suggested to be 
responsible for the hepatic glucuronidation of 40% of drugs, while UGTs 1A1, 1A4, and 
1A9 contribute to a further 47%. These results are not fully in line with a recent report 
suggesting that while many UGT2B enzymes are highly expressed in the liver, the levels 
of UGT1A enzymes are lower (Ohno and Nakajin, 2009). However, it is possible that 
UGT2B enzymes play a more significant role in the glucuronidation of endogenous 
compounds. 
 
 
Figure 4 Human hepatic UGT pie. Relative contributions of individual human liver UGT 
enzymes to the glucuronidation of 200 top prescribed drugs in the United States in 
2002. Reproduced from Williams et al. (2004a) and Burchell et al. (2005).  
Phenols. Glucuronidation of small planar phenols, such as 4-nitrophenol, α-naphthol, 
and scopoletin,  is catalyzed by most of the human UGT1A and UGT2B enzymes (Tukey 
and Strassburg, 2000). However, the highest activities have been observed with the UGT1 
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enzymes, with the exception of UGT1A4, while the activities of UGT2B enzymes towards 
phenolic substrates are generally 10- to 20-fold lower. Therefore, small planar phenols are 
often used as indicators of total UGT1A activity in human tissue microsomes. Many 
UGTs of subfamily 1A, such as UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A9, and 
UGT1A10, have overlapping substrate specificity in the glucuronidation of different 
phenols. While UGT1A6 preferentially conjugates small planar phenols, many larger, 
bulkier phenols are excellent substrates for UGT1A9 and the extrahepatic UGTs 1A7, 
1A8, and 1A10 (Ebner and Burchell, 1993; Luukkanen et al., 2005). Based on the finding 
that UGT1A enzymes are expressed throughout the GI tract, these enzymes have been 
proposed to have evolved to serve as a defense mechanism in the detoxification of many 
simple and complex phenols present in the digested matter (Tukey and Strassburg, 2000). 
Opioids. UGT2B7 is a major contributor to the glucuronidation of opioids (Tukey and 
Strassburg, 2000). When morphine glucuronidation was studied in detail, only UGT2B7 
catalyzed the formation of the pharmacologically active 6-O-glucuronide, while also many 
UGT1A enzymes, in addition to UGT2B7, catalyzed the formation of the inactive 3-O-
glucuronide (Stone et al., 2003). Interestingly, among other tissues, UGT2B7 is expressed 
also in the brain, indicating that the 6-O-glucuronide may contribute to the 
pharmacological activity of morphine (King et al., 2000).  
Steroids. UGT2B enzymes, especially UGT2B4, UGT2B7, UGT2B15, and UGT2B17, 
play a central role in the glucuronidation of different endo- and xenobiotic steroids such as 
androgens (C19 steroids), estrogens (C18 steroids), progestins (C21 steroids), and bile acids 
(C24 steroids) (Tukey and Strassburg, 2000; Turgeon et al., 2001). UGT2B4 and UGT2B7 
have a major role in the glucuronidation of C19 and C21 steroids and were found to be 
responsible for the conjugation hyodeoxycholic acid. In a recent study, UGT2A3 was also 
demonstrated to specifically glucuronidate bile acids (Court et al., 2008). UGT2B15 and 
UGT2B17 contribute significantly to the glucuronidation of testosterone and other 
androgens. Despite the central role of UGT2B enzymes in steroid metabolism, some 
UGT1A enzymes also catalyze the glucuronidation of steroids, including estrogens and 
androgens (Itaaho et al., 2008; Sten et al., 2009).  
Carboxylic acids. The clearance of the endogenous substrate bilirubin is highly 
dependent on a single UGT enzyme, UGT1A1 (Senafi et al., 1994). However, bilirubin 
seems to be the only carboxylic acid substrate of this particular UGT enzyme. Other 
UGT1A enzymes, mainly UGT1A3 and UGT1A9, have a central role in the formation of 
acyl-O-glucuronides from carboxyl-containing drugs (Kuehl et al., 2005). Furthermore, 
UGT2B4 and UGT2B7 contribute to the glucuronidation of carboxylic acid drugs such as 
nonsteroidal anti-inflammatory drugs.  
Amines. The contribution of various UGT enzymes to N-glucuronidation reactions is 
discussed in detail in Section 2.3. as well as under Results and Discussion.  
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2.2.5 Comparison of human and animal UGTs 
The majority of studies on recombinant UGTs in recent years have been performed using 
human enzymes, with animal UGTs receiving considerably less attention. Nonetheless, 
many in vitro studies conducted using liver microsomes have revealed significant 
differences between humans and various animal species in their ability to catalyze 
different glucuronidation reactions (Soars et al., 2001a; Soars et al., 2001b; Shiratani et al., 
2008). As an interesting detail, the domestic cat has a significantly lower capacity to 
glucuronidate many drugs and other xenobiotics than most other mammalian species 
(Court and Greenblatt, 2000). Overall, the reported interspecies differences and lack of 
animal UGT data highlight the importance of characterizing animal UGTs in more detail. 
UGT1A enzymes. The UGT1A gene complex is largely conserved among species 
(Mackenzie et al., 2003). Therefore, based on the limited cross-species data available and 
despite a few exceptions, the substrate specificity of the UGT1A enzymes across species 
appears to be similar (King et al., 2000). Especially the bilirubin-conjugating enzyme 
UGT1A1 is functionally similar across species (King et al., 1996).  
UGT1A6 gene is also highly conserved among several species, including humans, rats, 
mice, and rabbits (Mackenzie et al., 2005), and the respective enzyme catalyzes the 
glucuronidation of various simple phenolic compounds across species. However, in the 
domestic cat, UGT1A6 is a pseudogene (Court and Greenblatt, 2000). This finding 
explains the inefficiency of the domestic cat to glucuronidate planar phenols, and, 
furthermore, the susceptibility of this species to the toxic effects of some phenolic 
analgesic drugs such as paracetamol.  
Interspecies differences related to the UGT1A9 enzyme have also been reported. 
Propofol, a selective substrate of human UGT1A9, was glucuronidated efficiently by 
human, marmoset, and mouse liver microsomes, whereas its glucuronidation rate was low 
in the rat and undetectable in the dog (Soars et al., 2001a; Soars et al., 2001b; Shiratani et 
al., 2008). While human UGT1A9 and mouse Ugt1a9 code for functional enzymes, rat 
UGT1A9 is a pseudogene, explaining the low glucuronidation rates observed in rat liver 
microsomes. Entacapone, another excellent human UGT1A9 substrate, is also conjugated 
at high efficiency by human liver microsomes (HLM), but poorly by rat liver microsomes 
(Lautala et al., 1997; Lautala et al., 2000). These results indicate that the rat and the dog 
are not predictive species of human metabolism in the case of UGT1A9 substrates. 
Species differences related to the formation of quaternary ammoniumglucuronides (N+-
glucuronides) are marked. Trifluoperazine, a substrate of human UGT1A4, was 
extensively glucuronidated by HLM (Uchaipichat et al., 2006), whereas glucuronidation 
was undetectable in mouse and rat liver microsomes (Shiratani et al., 2008). This is in line 
with the finding that UGT1A4 is a functional enzyme in humans, while the respective 
genes in the rat and in the mouse are pseudogenes (Mackenzie et al., 2005). As opposed to 
many other animal species, the rabbit was reported to catalyze the formation of N+-
glucuronides (Bruck et al., 1997). This reaction was found to be catalyzed by rabbit 
UGT1A4 and UGT1A7. Interspecies differences related to N-glucuronidation are 
discussed further in Section 2.3. 
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UGT2B enzymes. In contrast to the UGT1A enzymes, the UGT2B enzymes are 
encoded by fully separate genes, and identifying orthologs of the human enzymes across 
species is challenging. Nonetheless, rat UGT2B1 and dog UGT2B1 appear to be orthologs 
of human UGT2B7. While in humans UGT2B7 catalyzes morphine 3-O-glucuronidation 
(Stone et al., 2003), rat UGT2B1 (King et al., 2000) and dog UGT2B31 (Soars et al., 
2003a) play a central role in morphine glucuronidation in these species.  
2.2.6 Inhibition and induction of UGTs 
UGT-mediated drug-drug interactions have been reported, at least at the in vitro level, for 
many drugs, including paracetamol, codeine, zidovudine, carbamazepine, lorazepam, and 
propafenone (Kiang et al., 2005). A general understanding seems to be, however, that, as 
opposed to drugs metabolized via CYPs, the likelihood of drug-drug interactions for drugs 
cleared by glucuronidation is low for two reasons (Williams et al., 2004a). Firstly, in 
many cases multiple UGT enzymes catalyze the glucuronidation of a single drug. 
Secondly, many UGT-mediated reactions have relatively high Michaelis constant (Km) 
values. More specifically, the Km values are higher than those generally observed for 
CYP-catalyzed reactions and in most cases considerably higher than therapeutic plasma 
levels. As a consequence, the in vivo exposure to the drug metabolized via UGTs rarely 
increases to more than twofold in the presence of a UGT inhibitor, whereas as much as 35-
fold increases have been observed for CYP-metabolized drugs in the presence of a potent 
CYP inhibitor. However, significant inhibitory interactions can occur when 
glucuronidation is a predominant metabolic elimination pathway, particularly if it is 
catalyzed by a single enzyme and when the therapeutic concentration of the inhibitor is 
close to the Ki of the target UGT (Remmel et al., 2008).  
In some cases, drugs and endogenous compounds, such as bilirubin, steroid hormones, 
and bile acids, compete for glucuronidation by an individual UGT enzyme, which 
potentially increases the concentrations of one or the other in plasma. As an example, 
toxic accumulation of the endogenous substance bilirubin, which is a pure UGT1A1 
substrate, has been reported after administration of the anticancer drug irinotecan because 
its active metabolite SN-38 is extensively metabolized by UGT1A1 (Tukey et al., 2002). 
Unlike inhibition of metabolizing enzymes, induction is a slow regulatory process 
involving nuclear receptors such as pregnane X receptor (PXR), constitutive androstane 
receptor (CAR), and the aryl hydrocarbon (Ah) receptor  (Xu et al., 2005). Activation of 
these regulatory elements increases the transcription of metabolizing enzymes, producing 
an increased amount of active enzymes. Xenobiotic nuclear receptors coordinately induce 
genes involved in all phases of xenobiotic metabolism, including oxidative metabolism, 
conjugation, and transport (Mackenzie et al., 2003; Bock and Kohle, 2004; Xu et al., 
2005; Zhou et al., 2005a). The mechanisms that regulate the tissue distribution and content 
of an individual UGT enzyme are currently largely unknown (Mackenzie et al., 2003). The 
process of induction of metabolizing enzymes results in an increased clearance via this 
route and thus lowered drug exposure. Some classical CYP inducers, such as 
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phenobarbital, phenytoin, and rifampicin, also induce many UGT enzymes. In addition, 
typical aromatic hydrocarbon-type inducers, such as 3-methylcholanthrene and β-
naphthoflavone, have been reported to induce UGT enzymes. 
2.2.7 UGT polymorphisms 
Genetic polymorphism has been described for several human UGT genes, including UGTs 
1A1, 1A6, 1A7, 2B4, 2B7, and 2B15 (Miners et al., 2002; Burchell, 2003; Guillemette, 
2003). According to current understanding, the polymorphisms related to UGT1A1 
enzyme are clinically most relevant. However, also other UGT polymorphisms have been 
shown to greatly affect enzyme activities, as in the case of a genetic variant of UGT2B17 
significantly affecting testosterone glucuronidation (Jakobsson et al., 2006). The most 
extreme case of the genetic variation of UGT1A1 is known as Crigler-Najjar syndrome 
(Mackenzie et al., 2003). Crigler-Najjar patients totally lack expression of the UGT1A1 
enzyme, leading to bilirubin-induced morbidity. Gilbert’s syndrome is another case of the 
genetic variation of UGT1A1. In this case, the polymorphic allele UGT1A1*28 is 
associated with reduced UGT1A1 enzyme activity, causing mild hyperbilirubinemia. The 
frequency of the UGT1A1*28 variant in Caucasians is 7-19% (Miners et al., 2002). 
Neonates with Gilbert's syndrome have a higher incidence of neonatal jaundice and more 
often require light therapy. Furthermore, Gilbert’s syndrome, or UGT1A1 polymorphism, 
has been associated with some clinically relevant toxic drug responses. As an example, a 
significantly higher incidence of neutropenia caused by reduced glucuronidation of a toxic 
metabolite of irinotecan has been reported (Tukey et al., 2002). To this end, FDA has 
approved a genotyping test to test UGT1A1 polymorphism of patients receiving irinotecan 
therapy. Atazanavir and indinavir, inhibitors of UGT1A1 in vitro, are other examples of 
drugs associated with a higher incidence of serious hyberbilirubinemia (Zhang et al., 
2005).  
2.2.8 Drug and xenobiotic toxicities related to UGTs 
Even though glucuronidation is generally considered a true detoxification process, some 
acyl and arylamine glucuronides have been associated with adverse drug effects. 
Acylglucuronides are formed from carboxyl-containing compounds, such as diclofenac, 
and other nonsteroidal anti-inflammatory drugs. It has been reported that some 
acylglucuronides are intrinsically reactive, i.e. they can spontaneously react at 
physiological pH by hydrolysis and intramolecular rearrangements (Sallustio et al., 2000; 
Bailey and Dickinson, 2003). These reactive metabolites can bind covalently to plasma 
proteins, tissue proteins, and nucleic acids, resulting in toxic reactions. Although direct 
evidence for the toxicity of acylglucuronides in vivo is scarce, acylglucuronides have been 
associated with many adverse drug effects, including hypersensitivity and cellular toxicity.  
24 
 
 
 
 
It has also been suggested that N-glucuronidation contributes to the carcinogenicity of 
some primary arylamines, such as the tobacco-related chemical benzidine (Zenser et al., 
1998; Zenser et al., 2002). Benzidine and related substances undergo direct 
glucuronidation in the liver and accumulate in the bladder as N-glucuronides. The N-
glucuronides are labile in the acidic pH of urine and are therefore hydrolyzed back to the 
initial aromatic amines. The newly formed aromatic amines are further bioactivated in the 
bladder to reactive species. Therefore, in this case, N-glucuronides seem to act as a 
“transport system” to deliver the toxic amines to urine, contributing to the carcinogenicity 
of these chemicals.  
2.3 N-Glucuronidation 
2.3.1 Overview 
Compounds with nitrogen-containing nucleophilic functional groups, such as primary 
aromatic amines, hydroxylamines, amides, sulfonamides, tertiary aliphatic amines, and 
aromatic N-heterocycles, are subject to N-glucuronidation (Fig. 5). N-Glucuronidation 
represents a major elimination pathway for many drugs, including lamotrigine, olanzapine, 
carbamazepine, amitriptyline, retigabine, tioconazole, and ketotifen (Hawes, 1998; 
Kassahun et al., 1998; Breyer-Pfaff, 2004; Staines et al., 2004; Borlak et al., 2006). 
Aromatic N-heterocycles, such as imidazoles, triazoles, and tetrazoles, are common 
structural motifs in current drug development, and many of these new drug candidates 
have also been reported to be metabolized via direct N-glucuronidation (Stevens et al., 
2001; Nakazawa et al., 2006; Yan et al., 2006). Furthermore, some toxic chemicals, e.g. 
primary arylamines and hydroxylamines, undergo N-glucuronidation. N-Glucuronides are 
generally safe, water-soluble metabolites, but, as mentioned earlier, in rare cases N-
glucuronidation may contribute to the carcinogenicity of primary arylamines (Zenser et 
al., 1998; Zenser et al., 2002). 
Marked differences across species have been observed in the ability to catalyze 
different N-glucuronidation reactions (Chiu and Huskey, 1998). In particular, the ability to 
form quaternary ammonium glucuronides (N+-glucuronides) from aliphatic tertiary amines 
seems to be largely restricted to humans and higher primates (Hawes, 1998). However, a 
variety of N-glucuronidation reactions are also catalyzed, at least to some extent, by 
monkey, rat, dog, and rabbit UGTs (Magdalou et al., 1992; Zenser et al., 1998). Some N-
glucuronide conjugates are formed especially efficiently by the rabbit liver (Magdalou et 
al., 1992; Uesawa et al., 2004; Kaji and Kume, 2005).  
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Figure 5 Some examples of nitrogen-containing structures subject to N-glucuronidation.  
The study of interspecies differences in N-glucuronidation is closely related to 
revealing which UGT enzymes catalyze these reactions. Green et al. were the first to 
report that one recombinant human UGT enzyme, namely UGT1A4, catalyzes different N-
glucuronidation reactions (Green et al., 1995; Green and Tephly, 1996; Green et al., 
1998). In particular, this enzyme was found to catalyze the formation of quaternary N-
glucuronides, the reaction limited to humans. Mainly based on these findings, UGT1A4 
has generally been considered an enzyme “specialized” in N-glucuronidation. 
Nonetheless, based on recent findings, it has become evident that other enzymes, such as 
UGT1A1, UGT1A3, UGT1A9, UGT2B4, and UGB2B7, may play a more important role 
in some N-glucuronidation reactions (Green and Tephly, 1998; Zenser et al., 2002; Staines 
et al., 2004; Girard et al., 2005; Kaji and Kume, 2005; Borlak et al., 2006; Rowland et al., 
2006; Omura et al., 2007; Alonen et al., 2008). In addition, based on observations on the 
biphasic in vitro kinetics of some N-glucuronidation reactions in HLM (Breyer-Pfaff et al., 
2000; Nakajima et al., 2002b), in some cases the UGT1A4-catalyzed glucuronidation 
might only explain the low-affinity reaction, while another UGT enzyme is responsible for 
the high-affinity reaction. In the following sections, interspecies differences and the 
human UGTs involved in different N-glucuronidation reactions are discussed in detail. 
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2.3.2 Primary arylamines and hydroxylamines 
A number of primary arylamines and hydroxylamines, including drugs and some toxic 
chemicals, are subject to N-glucuronidation (Fig. 6, Table 3). Humans and most animal 
species are capable of catalyzing the N-glucuronidation of this type of amines. More 
specifically, humans and dogs efficiently catalyzed the N-glucuronidation of primary 
arylamines and hydroxylamines, such as the carcinogens benzidine and N-hydroxy-2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP), while these reactions may 
be less important in the rat (Kaderlik et al., 1994; Zenser et al., 1998; Zenser et al., 2002). 
In fact, in the rat acetylation was the preferred pathway over N-glucuronidation in the 
metabolism of benzidine and N-OH-PhIP. The rabbit has also been shown to efficiently 
catalyze arylamine N-glucuronidation. As an example, the N-glucuronidation of 
afloqualone in rabbit liver microsomes was more efficient than in liver microsomes of any 
other species (Kaji and Kume, 2005). 
Characteristic to some primary arylamine N-glucuronides is their lability, as they 
rapidly hydrolyze under acidic or alkalic conditions (Ciotti et al., 1999). As an example, 
N-glucuronide of benzidine was hydrolyzed under acidic conditions within minutes. The 
hydrolysis rate of benzidine N-glucuronide was highly dependent on pH; 50% of 
glucuronide was hydrolyzed at pH 5.3 (at 37°C) within 5 min, whereas at pH 7.4 the half-
life of hydrolysis was >100 min. Plasma further stabilized the glucuronides, since >80% ot 
the conjugate remained after 4 h of incubation at 37°C. The issue of the stability of N-
glucuronide conjugates is important in the analysis of various in vitro or in vivo samples, 
as for example the acidic pH of either urine or the LC eluent used may hydrolyze the 
labile N-glucuronides.  
In humans, the N-glucuronidation of primary arylamines and hydroxylamines is 
primarily catalyzed by UGT1A1, UGT1A4, and UGT1A9, and possibly also by other 
UGT1A family enzymes, while the activities of UGT2B enzymes towards these substrates 
are low (Ciotti et al., 1999; Girard et al., 2005; Borlak et al., 2006). N-Glucuronidation of 
benzidine, N-acetylbenzidine, and 4-aminobiphenyl was shown to be catalyzed mainly by 
UGTs 1A9 and 1A4 (Ciotti et al., 1999). UGTs 1A1, 1A6, and 2B7 also glucuronidated 
these compounds, but the expression-normalized activities were low. In the case of N-OH-
PhIP, kinetic analyses and normalized activities revealed that human UGT1A1 was the 
predominant enzyme involved in the formation of the N2-glucuronide (hydroxylamine 
glucuronide) in the human liver, while UGT1A1 and UGT1A9 were involved in the 
formation of the less important N3-glucuronide (Girard et al., 2005). Moreover, UGT1A10 
was found as an important extrahepatic enzyme catalyzing N-OH-PhIP glucuronidation 
(Dellinger et al., 2007). Interestingly, N2-glucuronide, the major metabolite in humans, 
was resistant to β-glucuronidase, while the N3-glucuronide was hydrolyzed by β-
glucuronidase back to N-OH-PhIP, thus potentially increasing the carcinogenicity of this 
agent in vivo. Retigabine was conjugated to two regio-isomeric N-glucuronides at the 
primary (N2) and secondary (N4) arylamine groups (Borlak et al., 2006). UGT1A9 and 
UGT1A1 produced the N2-glucuronide, while the N4-glucuronide was produced only by 
UGT1A9.  Furthermore, UGT1A4 produced both N-glucuronides, but at a low rate.  
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Figure 6  Structures of N-glucuronidated drugs and xenobiotics. The glucuronidation site(s) is 
marked with an arrow and the major sites are indicated in boldface.  
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Table 3  Characteristics of N-glucuronidated drugs and other xenobiotics. 
Substrate Km, 
HLM 
(µM) 
% Dose 
excreted  
in human 
urine 
Species 
differences 
Human 
UGT(s) 
involved 
References  
Primary arylamines and hydroxylamines  
Afloqualone 2019 8 In vitro: rabbit >> 
human > dog ≈ rat 
≈ monkey 
UGT1A4 Kaji and Kume, 2005 
Benzidine 800 Major In vitro: human ≈  
dog > rat 
UGT1A4 
UGT1A9 
Zenser et al., 1998;  
Ciotti et al., 1999 
N-Acetylbenzidine 360; 
1070a 
Major In vitro: human > 
dog > rat 
UGT1A1 
UGT1A4 
UGT1A9 
Zenser et al., 1998;  
Ciotti et al., 1999 
N-OH-PhIP 23 Major  
(N2-G) 
In vivo (N2-G): 
human ≈ dog >> 
rat 
 
UGT1A1 
UGT1A10 
Kaderlik et al., 1994;  
Girard et al., 2005; 
Dellinger et al., 2007  
Retigabine 
 
145 16 (N2-G) 
2 (N4-G) 
In vivo: observed 
in human,  dog, 
rat 
UGT1A1 
UGT1A9 
Hempel et al., 1999;  
Borlak et al., 2006  
Amides and sulfonamides  
Carbamazepine 234 Major Observed in 
human, rat 
UGT2B7 Staines et al., 2004  
Dulcin 
 
2100 N.R. In vitro: rabbit > 
human 
UGT1A9 Uesawa et al.,  
2004 & 2007  
Perfluorooctane-
sulfonamide 
143 N.R. In vitro: human ≈ 
rat > monkey 
≈dog  
UGT2B7 Xu et al., 2006  
MaxiPost 
(developmental 
drug) 
6.4 17 In vivo: major in 
human, dog 
UGT2B7 Zhang et al., 2004  
Tertiary aliphatic amines 
Amitriptyline 1.4; 
310a 
3-14 In vitro:human, 
rabbit 
UGT1A4 Breyer-Pfaff et al., 
1997 & 2000  
Imipramine 97; 
700a 
<1 N.R. 
 
UGT1A4 Nakajima et al., 2002b  
Ketotifen  1.3; 
92a 
17-24 In vivo: human ≈ 
rabbit 
UGT1A4 Mey et al., 1999;  
Breyer-Pfaff et al., 2000  
Tamoxifen 36 N.R. In vitro: only in 
human (not in rat, 
mouse, guinea 
pig, dog, monkey) 
 
UGT1A4 Kaku et al., 2004  
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Table 3 (continued) 
 
Substrate Km, 
HLM 
(µM) 
% Dose 
excreted  
in human 
urine 
Species 
differences 
Human 
UGT(s) 
involved 
References  
Aromatic N-heterocycles  
FYX-051 
(developmental 
drug) 
64 43 (N1-G)  
16 (N2-G) 
In vivo: human ≈ 
monkey >> rat  
UGT1A9 Nakazawa et al,, 2006;  
Omura et al., 2007  
JNJ-10198409 
(developmental 
drug) 
1.2  
(Glu-A) 
N.R. In vitro: both Glu-
A and Glu-B 
formed in human, 
monkey, rat  
UGT1A4 
UGT1A9 
Yan et al., 2006  
Lamotrigine 1869; 
2234a 
63 (N2-G) 
Minor  
(N5-G)  
In vitro: human > 
rabbit >> monkey 
> rat 
UGT1A4 
UGT2B7 
Magdalou et al., 1992;  
Rowland et al., 2006  
Losartan 100 N.R. In vitro: human, 
rabbit, rat 
UGT1A1 
UGT2B7 
Alonen et al., 2008  
Midazolam 38 N.R. N.R. UGT1A4 Klieber et al., 2008  
RG 12525 
(developmental 
drug) 
 Major  
(N2-G) 
In vitro: human ≈ 
monkey >> rat 
UGT1A1 
UGT1A3 
Stevens et al., 2001  
N.R. = not reported 
abiphasic kinetics reported 
2.3.3 Amides and sulfonamides 
Various primary arylamides, cyclic amides, ureido compounds, and sulphonamides have 
been reported to undergo N-glucuronidation (Fig. 6, Table 3) in humans and many animal 
species, including rats, dogs, rabbits, and monkeys (Staines et al., 2004; Zhang et al., 
2004; Xu et al., 2006). As an example, N-glucuronide conjugate was found as a major 
metabolite of the cyclic amide MaxiPost, a developmental drug, in both humans and dogs 
(Zhang et al., 2004). The excretion of MaxiPost N-glucuronide was species-dependent, as 
in humans this conjugate was excreted via the urine, while in the dog it was mainly found 
in the bile. Furthermore, the N-glucuronidation of perfluorooctanesulfonamide, an 
environmental chemical, was studied in vitro across species, and liver microsomes of 
humans, dogs, monkeys, and rats catalyzed the reaction at comparable efficiencies (Xu et 
al., 2006).  In addition, the N-glucuronidation of dulcin, an ureido compound, was 
catalyzed by both human and rabbit liver microsomes (Uesawa et al., 2004; Uesawa et al., 
2007).  
Human UGT2B7 seems to play a significant role in the N-glucuronidation of this 
group of substances, including the aforementioned carbamazepine, perfluorooctane-
sulfonamide, and MaxiPost (Staines et al., 2004; Zhang et al., 2004; Xu et al., 2006). More 
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specifically, UGT2B7, which is highly expressed in the liver, kidney, and intestine, was 
suggested to be a major enzyme responsible for carbamazepine N-glucuronidation in all of 
the above-mentioned tissues (Staines et al., 2004). In the case of 
perfluorooctanesulfonamide, UGT2B7 and UGT2B4 catalyzed its N-glucuronidation in 
humans (Xu et al., 2006). Interestingly, rat UGT2B1, which shows a strong resemblance 
to the human UGT2B7 enzyme, catalyzed perfluorooctanesulfonamide N-glucuronidation 
in the rat. Rat UGT1.1 and UGT2B12 also contributed to the N-glucuronidation of this 
substance. Human UGT1A family enzymes 1A1 and 1A9 catalyzed dulcin N-
glucuronidation, while no contribution of UGT2B7 was detected (Uesawa et al., 2007). 
However, the affinities of the two UGT1A enzymes towards dulcin were low, suggesting 
the contribution of other, currently unknown UGTs in this reaction. Rabbit UGT1A7 and 
2B17 also catalyzed dulcin N-glucuronidation (Uesawa et al., 2004; Uesawa et al., 2007).  
2.3.4 Tertiary aliphatic amines 
In humans, N+-glucuronidation contributes significantly to the metabolism of many 
aliphatic tertiary amine drugs, such as antihistamines, tricyclic antipsychotics, and 
antidepressants (Luo et al., 1991; Chiu and Huskey, 1998) (Fig. 6, Table 3). While N+-
glucuronidation is efficient in humans, this reaction is generally not observed in most 
animal species, including rats, mice, guinea pigs, dogs, and cynomolgus monkeys (Soars 
et al., 2001b; Kaku et al., 2004; Shiratani et al., 2008). Nonetheless, some animal species, 
such as higher primates (chimpanzees), marmoset monkeys, and rabbits, have been 
reported to efficiently catalyze N+-glucuronidation of a number of drugs, including 
cyproheptadine, ketotifen, amitriptyline, imipramine, and chlorpromazine (Coughtrie and 
Sharp, 1991; Chiu and Huskey, 1998; Soars et al., 2001a). These results suggest that the 
rabbit or the marmoset could be suitable animal models in the development of drugs that 
undergo N+-glucuronidation, as they are predictive of human metabolism via this route.  
Human UGT1A4 catalyzes the N+-glucuronidation of many tertiary amine drugs, 
including amitriptyline, ketotifen, diphenhydramine, imipramine, and tamoxifen (Green 
and Tephly, 1996; Breyer-Pfaff et al., 2000; Kaku et al., 2004). Moreover, UGT1A3 has 
been reported to catalyze N+-glucuronidation, but at a lower efficiency than UGT1A4 
(Green et al., 1998). While catalyzing different N-glucuronidation reactions seems to be a 
major type of activity for UGT1A4, UGT1A3, a close homolog of UGT1A4, is also 
involved in different O-glucuronidation reactions. Residues 36 and 40 of UGT1A3 and 
UGT1A4 have been reported to be crucial for the selectivities of these enzymes towards 
planar phenols and tertiary amines, respectively (Kubota et al., 2007). Rabbit UGT1A4, 
along with UGT1A7, also catalyzed imipramine N+-glucuronidation (Bruck et al., 1997), 
further supporting the similarity between humans and rabbits with respect to this 
metabolic route. However, in many animal species, including rats and mice, UGT1A4 is 
not a functional enzyme (Mackenzie et al., 2005), which in part explains the significant 
interspecies differences observed in N+-glucuronidation.   
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Although UGT1A4 catalyzes many N+-glucuronidation reactions, other UGT enzymes 
also appear to be involved in this reaction. Detailed kinetic experiments revealed that the 
N+-glucuronidation of some amines, including amitriptyline, ketotifen, diphenhydramine, 
and imipramine, by HLM obeyed biphasic kinetics (Breyer-Pfaff et al., 1997; Mey et al., 
1999; Breyer-Pfaff et al., 2000; Nakajima et al., 2002b). The measured high- and low-
affinity Km values are listed in Table 3. The biphasic kinetic curves suggested that at least 
two different UGT enzymes contribute to each of these reactions. Further studies 
conducted using different human recombinant UGT enzymes indicated that the UGT1A4-
catalyzed reaction only explained the low-affinity component of the HLM-catalyzed 
reaction. Therefore, another, still unknown UGT enzyme probably catalyzes the high-
affinity glucuronidations of these substrates in the human liver. 
2.3.5 Aromatic N-heterocycles 
A number of aromatic N-heterocycles containing five- and six-membered rings such as 
imidazoles, pyrazoles, triazines, tetrazoles, and pyridines are subject to N-glucuronidation 
(Fig. 6, Table 3). Due to the structural diversity of this group of substances, their N-
glucuronidation across species and the human UGTs catalyzing the reactions are highly 
compound-dependent. Nevertheless, in many cases humans and monkeys glucuronidate 
aromatic N-heterocycles at comparable rates (Stevens et al., 2001; Nakazawa et al., 2006; 
Yan et al., 2006). Rats, at least in some cases, lack the ability to N-glucuronidate these 
compounds (Magdalou et al., 1992; Stevens et al., 2001; Nakazawa et al., 2006).  
The N-glucuronidation of FYX-051, a developmental drug, was studied in vivo in 
humans, monkeys, rats, and dogs (Nakazawa et al., 2006). Triazole N1-glucuronide was 
found to be the predominant metabolite in human and cynomolgus monkey urine, 
accounting for ∼40% of the dose, whereas the N2-glucuronide accounted for ~10-20%. In 
the rat, only low levels of N-glucuronides were detected. Interestingly, in dogs the major 
metabolites were N1- and N2-glucosides, i.e. conjugation of the triazine nitrogens with 
glucuronic alcohol instead of glucuronic acid. In the case of RG 12525, another 
developmental drug, the tetrazole N2-glucuronide was the predominant metabolite in 
humans and monkeys, while only low levels of glucuronides were observed in rat 
hepatocytes (Stevens et al., 2001). In humans, also another regioisomeric glucuronide at 
the N1 was formed, but at lower levels. Losartan, another tetrazole, was conjugated to two 
regioisomeric N-glucuronides (Alonen et al., 2008) by human, rabbit, and rat liver 
microsomes. Tetrazole N2 was the preferred site of glucuronidation in all of the above-
mentioned species. Furthermore, nafimidone alcohol was conjugated to an imidazole N-
glucuronide in cynomolgus monkeys, baboons, and humans, while this metabolite was not 
detected in dog urine (Rush et al., 1990). Lamotrigine, an antiepileptic drug, was 
conjugated efficiently at the triazine ring by human, rabbit, and guinea-pig liver 
microsomes, whereas only low levels of glucuronide were found in Rhesus monkeys and 
rats (Magdalou et al., 1992). Finally, efficient N-glucuronidation of 1-phenylimidazole at 
N3 was observed in liver microsomes of many species, including humans, rats, guinea-
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pigs, rabbits, but not dogs (Vashishtha et al., 2002). The affinities in all species were, 
however, rather poor (Km 0.6-4.4 mM). 
Several UGT enzymes, including UGT1A1, UGT1A3, UGT1A4, UGT1A9, and 
UGT2B7, contribute to the glucuronidation of various N-heterocycles. Firstly, UGT1A4 
and UGT2B7 were suggested as the primary enzymes catalyzing the N-glucuronidation of 
lamotrigine, a reaction obeying atypical kinetics in HLM (Rowland et al., 2006). While 
both enzymes glucuronidated lamotrigine at rather poor affinities (Km ∼2 mM), inhibition 
studies indicated that the UGT2B7-catalyzed reaction might dominate at low substrate 
concentrations. Midazolam, a sedative agent metabolized mainly by CYPs, was found to 
undergo N-glucuronidation at the tertiary imidazole group (Klieber et al., 2008). This 
reaction was catalyzed most efficiently, in terms of non-normalized glucuronidation rates, 
by UGT1A4. The role of  UGT1A4 in midazolam glucuronidation was further supported 
by comparable Km values of UGT1A4 and HLM, ∼30-40 µM. FYX-051 glucuronidation 
at N1 was catalyzed by human UGT1A9, while very low (non-normalized) activities were 
measured for UGT1A1 and UGT1A7 (Omura et al., 2007). However, the Km values of 
UGT1A9 and HLM towards FYX-051 N1-glucuronidation were dissimilar. UGT1A1, 
UGT1A3, and UGT2B7 catalyzed the formation of the tetrazole N2-glucuronide of RG 
12525 (Stevens et al., 2001), but as only a limited amount of UGT enzymes were tested 
and kinetic parameters were not measured, the contribution of other enzymes to this 
reaction cannot be excluded. Finally, UGT1A1 and UGT2B7 were the main contributors 
to tetrazole N2-glucuronidation of losartan in the human liver (Alonen et al., 2008).  
2.4 Approaches for studying drug glucuronidation 
A schematic illustration of different approaches for studying drug glucuronidation is 
presented in Fig. 7. Computational (“in silico”) methods can be used as rapid screens for 
the substrate selectivity of individual UGTs. However, structure–activity relations (SAR) 
of UGT enzymes are currently poorly understood, limiting their use. Different in vitro 
approaches, such as incubations with liver microsomes and recombinant UGT enzymes, 
provide the tools for reaction phenotyping and the study of interspecies differences. Using 
in vitro – in vivo scaling (IVIVS), an indication of the importance of glucuronidation on 
an in vivo scale can be produced. In vivo studies ultimately reveal the contribution of this 
metabolic route to the overall elimination of a drug.  
 Figure 7 A schematic illustration of drug glucuronidation studies. 
2.4.1 In silico modeling 
Computational modeling potentially provides an economical alternative to laborous and 
time-consuming laboratory-based techniques for studying the structure-function relations 
of drug metabolism (van de Waterbeemd and Gifford, 2003). In silico modeling can be 
used as a high-throughput screen at the early stages of drug development to predict which 
enzymes metabolize the drug candidates. In comparison with CYP-catalyzed reactions, the 
structure-function relations of UGT enzymes are, however, generally poorly understood, 
complicating the computational prediction of UGT-mediated metabolism (Miners et al., 
2004; Smith et al., 2004). The relatively small number of reports available on the 
modeling of UGT enzymes indicates a scarcity of appropriate experimental data for these 
purposes and explains why little progress has been made in this area in recent years. 
Moreover, existing evidence suggests that individual UGT isoforms exhibit unique, but 
overlapping substrate selectivity, further complicating the building of reliable models. 
Nonetheless, some two-dimensional (2D), quantum mechanical, and pharmacophore 
models permitting the classification of UGT substrates have been developed for a number 
of human UGTs such as 1A1, 1A4, 1A6, and 1A9 (Ethell et al., 2002; Sorich et al., 2002; 
Smith et al., 2003). These approaches demonstrate that computational prediction of UGT 
enzyme substrate selectivity is possible. The biggest obstacle for UGT modeling at present 
is probably that X-ray crystal structures of UGT enzymes are unavailable. Furthermore, 
only a few structurally or catalytically relevant amino acids have been identified in the 
structures of the UGT enzymes. However, crystallization technology is a rapidly 
developing area, and, recently, techniques to crystallize membrane-bound enzymes, 
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including CYPs, have been successfully utilized (Williams et al., 2003; Williams et al., 
2004b). The docking of ligands into protein structures has been used in reaction 
phenotyping of CYP substrates, suggesting that such technologies could also be applied in 
the UGT field (Sorich et al., 2008).  
2.4.2 In vitro approaches 
2.4.2.1 Microsomes isolated from liver and other tissues 
Microsomes are subcellular fractions isolated from hepatic and extrahepatic tissues by 
differential ultracentrifugation (Ekins et al., 1999). The microsomal fraction contains both 
UGT and CYP enzymes, as they are located in the endoplasmic reticulum of the cells. 
Liver microsomes are regarded as the “golden standard” of metabolic stability testing in 
drug development, since they contain the major drug-metabolizing enzymes as a 
“concentrate” (Brandon et al., 2003; Plant, 2004; Pelkonen and Raunio, 2005). Liver 
microsomes isolated from humans and a wide variety of animal species, as well as 
microsomes isolated from other tissues, such as the intestine and kidney, are currently 
commercially available.   
Microsomal glucuronidation studies are performed by adding the drug under 
investigation along with the cofactor UDPGA and the enzyme source, human or animal 
liver microsomes, to the incubation buffer, generally phosphate or Tris buffer pH 7.4 with 
Mg2+ (Remmel et al., 2008). The samples are incubated at 37°C typically for 0.5-1 h. 
Many drugs and xenobiotics are highly lipophilic and therefore poorly soluble in water. 
Organic solvents, such as acetonitrile, methanol, or dimethyl sulfoxide, can be used to 
dissolve the substrates. As high concentrations of organic solvents tend to decrease 
microsomal UGT activities (Dehal et al., 2003), <1% solvent concentration is generally 
desirable. Whereas the total CYP content of the microsomes can easily be determined, no 
such method exists for UGTs. Therefore, the incubations are “standardized” by the 
addition of the same amount of protein (typically 0.25–1.0 mg protein per ml) to each 
incubate. In general, the enzyme is stable up to 45 min to 1 h, and an even longer 
incubation time may be used for slow reactions. When conducting enzyme kinetic studies, 
the linearity of glucuronide formation with respect to incubation time and protein 
concentration should be determined for each studied reaction in each studied enzyme 
source. It is recommended that at least ten different substrate concentrations ranging from 
0.2×Km to 10×Km be used, and that less than 10% of the substrate be consumed during the 
incubation (Cornish-Bowden, 1995). An excess (1-5 mM) of UDPGA is added to ensure 
that depletion of the cofactor does not limit the reaction rates. 
In contrast to the CYPs, the active site of UGTs is in the lumen of the endoplasmic 
reticulum (Clarke and Burchell, 1994). Therefore, at least for a portion of the isolated 
microsomes, the active site of the UGT enzyme remains in its “normal configuration” 
entrapped within the vesicle. Therefore, UGT activity in the microsomes is latent, and 
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maximal activity is not obtained until the integrity of the membrane is disrupted 
(Banhegyi et al., 1993). Disrupting the membrane will allow the cofactor UDPGA the 
access to the active site. Traditionally, detergents, such as Brij 58, Lubrol, or Triton X- 
100, or sonication have been used to remove the latency (Winsnes, 1969; Burchell and 
Coughtrie, 1989). However, high concentrations of detergents decrease UGT enzyme 
activities. The use of detergents is therefore time-consuming, as the optimal concentration 
has to be sought individually for each detergent – microsome – substrate combination. 
Recently, many investigators have switched to the use of the pore-forming 20-amino acid 
peptide alamethicin, which has a broader optimum concentration (typically 25-100 µg/mg 
protein) (Fisher et al., 2000). Alamethicin is pre-incubated together with the microsomes 
and buffer on ice for 30–35 min, or at 37°C for 10 min, prior to the addition of the 
substrate and UDPGA. Removing the latency typically increases the reaction rates from 
two- to fivefold (Fisher et al., 2000; Soars et al., 2003b). CYP marker activities in 
microsomes are reportedly unaffected by treatment with alamethicin, suggesting its 
usability in metabolic stability testing (Yan and Caldwell, 2003).  
Saccharolactone and albumin are other agents, that can be added to the microsomal 
incubates in some cases. Saccharolactone inhibits microsomal β-glucuronidase from 
hydrolyzing the formed glucuronide conjugates. However, recent findings discourage the 
use of saccharolactone routinely in the incubates, as the extent of hydrolysis was found to 
be relatively small (9–19% of the glucuronide formation rate), and higher saccharolactone 
concentrations, in turn, resulted in a modest degree of inhibition of some glucuronidation 
reactions (Oleson and Court, 2008). Adding bovine serum albumin or fatty acid-free 
human serum albumin to HLM incubates was reported to decrease the Km for zidovudine 
glucuronidation by an order of magnitude (Rowland et al., 2007; Rowland et al., 2008). 
Microsomes contain fatty acids, which were reported to act as potent competitive 
inhibitors of some UGTs, such as UGT2B7, and albumin “binds” these fatty acids, thus 
decreasing their binding to the UGT enzymes.  
2.4.2.2 Recombinant UGTs 
Several expression systems for different UGT enzymes have been described (Guengerich 
et al., 1997; Radominska-Pandya et al., 2005a). These expression systems utilize cell lines 
that inherently express minimal levels of the respective proteins. The mammalian-derived 
cell lines used for these purposes include Chinese hamster lung fibroblasts (V79), human 
embryonic kidney cells (HEK293), and human B-lymphoblastoid cells (AHH-1). 
Moreover, insect cell lines (Sf9) expressing UGTs have been developed. To produce such 
expression systems, the cDNA encoding an individual UGT enzyme is inserted into the 
cells using virus vectors, and the cells are cultured to produce sufficient amounts of the 
UGT enzymes. At present, several recombinant human UGT enzymes are commercially 
available.  
The incubation conditions described earlier for liver microsomes can essentially be 
applied to recombinant UGT experiments. Like microsomal preparations, recombinant 
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UGT systems have been reported to be sensitive to the inhibitory effects of organic 
solvents, saccharolactone, and albumin during incubations (Dehal et al., 2003; Oleson and 
Court, 2008; Rowland et al., 2008). Apart from incubation conditions, many other factors, 
such as the transfection method (i.e. transient or stable), the cell line, and the membrane 
preparation (microsomes or whole-cell extracts) have an effect on the final enzyme 
activity of the recombinant UGT system, complicating comparison of results produced by 
different expression systems and laboratories (Guengerich et al., 1997; Tukey and 
Strassburg, 2000; Remmel et al., 2008). Insect cells transfected with baculovirus are 
excellent in terms of protein production, but enzyme activity tends to be low compared 
with mammalian cells systems. Significant amounts of inactive protein appear to be 
present in insect cell expression systems due to either poor membrane insertion or 
improper folding. Another issue regarding recombinant UGT preparates is that, as in the 
case of liver tissue, microsomal preparations can be isolated from these preparations; 
however, the yield of microsomal protein is often low. The use of whole-cell lysate as 
such or after sonication appears to be a good alternative and is easier than preparing 
microsomes.  
To be able to evaluate the contribution of different UGT enzymes in the 
glucuronidation of a single substrate, it is important to normalize the measured UGT 
activities. Normalization, i.e. dividing the measured activities of each UGT enzyme by 
their expression levels, allows for the direct comparison of the activities. In the case of 
UGT1A enzymes, the expression levels can be measured by Western blotting using 
antibodies directed against the UGT1A constant region. However, comparison between 
the UGT1A and UGT2B enzymes is not possible with this method. Nonetheless, a 
recently described system of expressing UGTs with histidine molecule tags (His-tags) 
allows direct comparison of expression levels of both UGT1A and UGT2B enzymes 
(Kurkela et al., 2003; Kurkela et al., 2007).  
Another issue complicating UGT reaction phenotyping is that the quantitative levels of 
different UGT enzymes in the human liver (or intestine) are currently unknown, although 
some estimates can be given based on mRNA levels (Nakamura et al., 2008; Ohno and 
Nakajin, 2009). Therefore, the best tools for determining the major UGT enzymes 
involved in each reaction at the moment include comparison of Km values observed in 
HLM vs. different recombinant UGTs, and comparison of normalized activities of 
individual UGTs towards the substrate (Miners et al., 2006).   
2.4.2.3 Primary hepatocytes 
Primary hepatocytes are intact and fully functional cells containing the complete set of 
phase I and II metabolic enzymes and transporter proteins. As hepatocytes are fully 
functional cells, endogenous cofactors, such as UDPGA, are produced within the cells. 
Overall, hepatocytes provide a system with a strong resemblance to the in vivo liver. 
Hepatocytes are therefore routinely used in drug metabolism studies to evaluate the 
contribution of different metabolic routes, including UGT-mediated metabolism, to the 
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elimination of drug candidates (Vermeir et al., 2005; Hewitt et al., 2007). Hepatocyte 
studies are often used also in the predictions of in vivo hepatic clearance (McGinnity et al., 
2004; Kilford et al., 2009). Culturing hepatocytes requires demanding laboratory 
techniques, limiting their use in routine metabolic stability testing. Moreover, the use of at 
least human primary hepatocytes is limited by the restricted availability of fresh liver 
tissue. Nonetheless, the techniques to prepare cryopreserved hepatocytes have recently 
developed to a point where the viabilities of cryopreserved cells are quite acceptable 
(LeCluyse et al., 2005). Moreover, pooled human hepatocytes from 5 or 10 donors are 
currently available, which decreases the variation between the batches.   
2.4.2.4 Liver cell lines 
Various permanent liver cell lines derived from primary tumors are less popular in drug 
metabolism studies mainly due to their incomplete expression of metabolic enzymes 
(Brandon et al., 2003; Vermeir et al., 2005). Compared with primary hepatocytes, the 
advantage of different cell lines is reproducibility. Moreover, cells lines are generally 
easier to culture and they maintain enzyme levels for a longer period. The best-
characterized human hepatoma cell line is HepG2. This cell line was recently reported to 
express many UGT2B family enzymes, including 2B4, 2B7, 2B10, 2B11, 2B15, 2B17, 
and 2B28 (Nakamura et al., 2008). However, the expression of UGT1A family enzymes 
was limited to 1A1 and 1A3. Another human hepatoma-derived cell line, HepaRG, has 
also been introduced (Gripon et al., 2002). The activities of major CYPs are relatively 
high in this cell line, making it a very promising candidate for in vitro drug metabolism 
studies (Kanebratt and Andersson, 2008). The HepaRG cell line was also reported to 
catalyze some UGT-mediated reactions (Aninat et al., 2006). 
2.4.3 In vivo studies 
Even though in vitro studies generally predict in vivo metabolism quite well, in vivo 
studies are an important part of drug development to confirm the major metabolic routes 
of a new drug candidate, and, moreover, to identify unexpected metabolic routes (Iyer and 
Zhang, 2008). When glucuronide conjugates are formed in vivo, the portion of the 
conjugates excreted via bile to the GI tract is subject to hydrolysis catalyzed by bacterial 
β-glucuronidase in the intestinal flora. The vulnerability of the glucuronides to hydrolysis 
by β-glucuronidase is compound-dependent. While some glucuronides are extremely 
resistant to β-glucuronidase (Sinz and Remmel, 1991; Kassahun et al., 1998), others are 
readily hydrolyzed by this enzyme back to pharmacologically active agents (Hiller et al., 
1999; Mey et al., 1999). After hydrolysis, the newly formed drugs can be absorbed back to 
systemic circulation. This mechanism has been reported to lead to significant 
enterohepatic circulation of some drugs.  
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Another important issue with regard to in vivo studies involving glucuronide 
conjugates is to evaluate whether the formed glucuronide conjugates are stable in plasma 
and excreta samples during sample pre-treatment. As an example, some glucuronides, 
such as the N-glucuronides of primary arylamines, are hydrolyzed in acidic or alkalic 
conditions within minutes (Ciotti et al., 1999). Furthermore, some glucuronides are rapidly 
hydrolyzed by bacterial β-glucuronidase present in fecal samples. If such hydrolysis 
occurs, the contribution of glucuronidation to the overall metabolism may be considerably 
underestimated. 
2.4.4 Glucuronide analytics 
Three basic methods have been used to analyze glucuronide conjugates from in vitro or in 
vivo samples (Remmel et al., 2008):  
(1) Radiometric methods using either radiolabeled cofactor (14C-UDPGA) or 
substrate followed by either thin-layer chromatography (TLC) or liquid 
chromatography (LC) to separate the glucuronide;  
(2) LC with ultraviolet detection (UV) or mass spectrometry (MS); 
(3) Fluorometric methods using fluorescent substrates, such as 1-naphthol. 
Radiometric methods have been widely employed for screening assays. A major 
advantage of these methods is that metabolite standard is not needed for the quantitation of 
the formed glucuronide product(s). The universal method is to use radiolabeled 14C-
UDPGA as the cofactor, resulting in labeled glucuronide product(s). The glucuronides can 
be separated from 14C-UDPGA by TLC (Bansal and Gessner, 1980) or LC (Coughtrie et 
al., 1986). When TLC is utilized, radioactivity on the plates is counted on a plate scanner, 
or by densitometric quantitation on film or a phosphoimager. In LC analyses, the 
glucuronides are detected using either an online flow scintillation analyzer (FSA) or 
fraction collection followed by liquid scintillation counting. Reversed-phase (C18) 
columns can generally be used for the separation of the glucuronide conjugates. As an 
alternative to TLC and LC methods, a method utilizing 14C-UDPGA and separation of the 
glucuronide products by solid-phase extraction (SPE) using 96-well extraction plates was 
recently introduced (Di Marco et al., 2005). Radiolabeled substrates can also be used 
instead of 14C-UDPGA, but are rarely available. Radiolabeled drugs are, however, 
synthesized in many cases for the purpose of mass balance and excretion studies of new 
drug candidates.  
Most glucuronides have very similar absorbance spectra as their aglycones (glucuronic 
acid does not contribute to UV absorption at wavelengths >210 nm), suggesting that one 
can construct a standard curve with the aglycone to quantitate the glucuronides during LC-
UV analyses. However, this method can only be used for the estimation of glucuronide 
levels. For proper quantitation, an authentic glucuronide standard is required. 
Alternatively, the glucuronide fraction can be collected and hydrolyzed with β-
glucuronidase, followed by quantitation of the glucuronide as the formed aglycone 
substrate. Treatment with β-glucuronidase can also be used to ensure that the peak 
observed in the chromatogram is in fact a glucuronide. However, some glucuronides, such 
as the N-glucuronide conjugates of lamotrigine (Sinz and Remmel, 1991) and olanzapine 
(Kassahun et al., 1998), are resistant to β-glucuronidase hydrolysis.  
The advantage of different LC-MS methods is that they are generally far more 
sensitive than any other methods. However, an authentic glucuronide standard is always 
needed for quantitative purposes by LC-MS. Glucuronides readily fragment, with a neutral 
loss of 176 amu, to produce the aglycone fragment. Glucuronides are weak acids, having a 
pKa of ∼4, and can thus generally be detected using negative ion mode at pH 4.5 or higher 
with electrospray ionization. Many glucuronides, at least when the substrate is a weak 
base, can also be detected using positive ion mode.  
The use of fluorometric methods is limited to the cases where the aglycone substrate is 
fluorescent. Moreover, as the aglycone substrate and the glucuronide product are not 
separated, their fluorescence characteristics should be different. Fluorometric methods for 
some fluorescent phenolic substrates, such as 1-naphthol, have been described (Mackenzie 
and Hanninen, 1980), and they have been applied for continuous fluorometric monitoring 
of glucuronide formation. 
2.4.5 Enzyme kinetics 
Traditionally, the initial enzyme velocity data of in vitro kinetic experiments have been 
fitted to the classical Michaelis-Menten equation (1) (Cornish-Bowden, 1995):  
 
SK
SVv
m +
×= max     (1), 
where v is the reaction velocity, Vmax the maximum velocity, Km the Michaelis 
constant, and S the substrate concentration. 
However, many CYP- and UGT-catalyzed reactions have been reported to obey non-
Michaelis-Menten kinetics (Houston and Kenworthy, 2000; Hutzler and Tracy, 2002; 
Atkins, 2004). Some of these “atypical” kinetic plots are presented in Fig. 8. Hill equation 
(2) can be used to describe sigmoidal kinetics indicating autoactivation:  
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where n is the Hill coefficient describing the degree of sigmoidicity (n>1). The 
mechanism of autoactivation kinetics is largely unknown, but can involve multiple 
substrates present in the active site of a single enzyme (Korzekwa et al., 1998).  
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 Figure 8 Typical and atypical kinetic plots, modified from Atkins (2004). Classical hyperbolic 
Michaelis-Menten kinetics (A); sigmoidal kinetics (B); substrate inhibition kinetics 
(C); and biphasic kinetics (D). In each case, the inset is the corresponding Eadie–
Hofstee plot of velocity versus velocity/substrate concentration (v/S). 
Substrate inhibition, another atypical kinetic phenomenon often observed in in vitro 
experiments, is described by the equation: 
 
)/()/(1
max
sim KSSK
Vv ++=    (3), 
 
where Ksi is the constant describing the substrate inhibition interaction. Although the 
mechanisms leading to substrate inhibition have not been fully revealed, a two-site model 
in which one binding site is productive and the other site is inhibitory and operable at high 
substrate concentrations has been suggested (Houston and Kenworthy, 2000). The 
operation of these two different binding sites results in decreased velocity with increasing 
concentrations. Detailed kinetic studies of human UGT1A enzymes have indicated another 
mechanism, where binding of the aglycone substrate to the enzyme-UDP complex leads to 
a nonproductive dead-end complex that slows the productive cycle (Luukkanen et al., 
2005). Generally, the observed Ksi values for substrate inhibition are high compared with 
the apparent Km values of the reactions, suggesting that in many cases substrate inhibition 
may not be relevant in vivo. 
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The third atypical kinetic mechanism suggested is a biphasic saturation profile 
indicative of an enzyme with both low- and high-affinity binding components, described 
by the equation:  
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where subscripts 1 and 2 denote the high- and low-affinity component of the reaction, 
respectively. Biphasic kinetics can be observed either when two different enzymes take 
part in the reaction, as frequently observed in tissues microsomes, or when a single 
enzyme has multiple binding regions (Houston and Kenworthy, 2000). 
Whether the atypical kinetics observed with UGT-catalyzed reactions actually reflects 
the intrinsic properties of the enzyme(s) or whether it is an artifact arising from the 
incubation conditions has been debated. To this end, Soars and coworkers (2003b) 
performed a detailed kinetic study using different incubation conditions for a set of 
glucuronidated model substrates. They concluded that atypical kinetics did not originate 
from the incubation conditions, and recommended that equations beyond the Michaelis-
Menten equation should be used to fit kinetic data to obtain an accurate estimate of in vitro 
glucuronidation, which in turn will also potentially improve the predictability of in vivo 
clearance.  
2.4.6 In vitro – in vivo scaling (IVIVS) 
The quantitative role of different metabolic pathways in the elimination of drugs can be 
estimated by extrapolating the measured in vitro kinetic data to the in vivo situation. 
Metabolic clearance (intrinsic clearance, CLint, in vitro) is an important parameter used in the 
scaling, and under linear velocity conditions (when S<<Km) is equal to the following ratio 
(Houston, 1994): 
 
m
max
vitro in int, K
VCL =     (5). 
 
CLint is a direct measure of the efficacy of an enzyme to metabolize a given substrate. 
When a drug is metabolized via several routes, the total clearance is the sum of these 
routes:  
 
i
n
i
tot CLCL
1=
∑=    (6). 
 
After determining CLint, in vitro, the first step in the IVIVS process is the use of different 
scaling factors (Barter et al., 2007). In the case of liver microsomal experiments, two 
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scaling factors, namely microsomal content per gram liver (MPPGL) and liver weight per 
kg body weight (wL) , are used to obtain in vivo CLint as follows: 
 
Lvitro in int,vivo  in int, wMPPGLCLCL ××=  (7). 
 
As only the free (unbound) drug is subject to metabolism, free fractions of the drug in 
blood (fu, b) and microsomes (fu, in vitro) are taken into account when the unbound in vivo 
clearance is estimated (Obach, 1997; Grime and Riley, 2006):  
 
vitro in u,
bu,vivo in int,
u  vivo, in int, f
fCL
CL
×=    (8). 
 
As the free fractions are generally measured from plasma samples, the free fraction in 
blood can be calculated from the plasma data as follows:  
 
b
pu,
b u, R
f
f =    (9), 
  
where fu, p is the free fraction in plasma and Rb the blood-to-plasma partition ratio. 
Finally, an appropriate liver model is used to calculate an estimate for in vivo hepatic 
clearance, CLH. The well-stirred model (Pang and Rowland, 1977), the simplest liver 
model taking into account the hepatic blood flow, QH, is described by the following 
equation: 
 
Hu vivo, in int,
Hu vivo, inint,
H QCL
QCL
CL +
×=   (10). 
 
Both microsomal and hepatocyte data have been widely used for scaling purposes 
(Soars et al., 2002; McGinnity et al., 2004; Brown et al., 2007; Kilford et al., 2009). Many 
studies indicate that hepatocyte data give more accurate predictions of in vivo metabolic 
clearance than microsomal data (Soars et al., 2002; Brown et al., 2007). However, in many 
cases, both the hepatocyte and the microsomal data tend to underpredict the in vivo 
metabolic clearance. For hepatocytes, cryopreserved human cells were reported to retain 
on average 94% of the CLint determined in fresh cells, indicating that both fresh and 
cryopreserved human hepatocytes may be used for the prediction of human hepatic 
clearance (McGinnity et al., 2004). With regard to liver microsomal data, improved 
predictability of microsomal data for drugs eliminated via glucuronidation was observed 
when alamethicin and bovine serum albumin were added to the incubates (Kilford et al., 
2009). Bovine serum albumin sequesters the fatty acids released during microsomal 
incubations that inhibit at least UGT1A9- and UGT2B7-mediated metabolism.  
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2.5 Investigated compounds 
2.5.1 4-Arylalkyl-1H-imidazoles 
The studied 4-arylalkyl-1H-imidazoles are a family of closely related structures (Fig. 9) 
that mediate their pharmacological effect by either activating or inhibiting the central α2-
adrenoceptors. These compounds are rather small (molecular weight ∼200) and relatively 
lipophilic (logP ∼2.5−2.8), indicating good permeability, and thus, have the ability to pass 
through the blood-brain barrier. The imidazole moiety makes the compounds slightly 
basic, with a pKa of ∼7.0-7.2, suggesting that even though both non-ionized and ionized 
form are present at a physiological pH of 7.4, the non-ionized form prevails. As free bases, 
4-arylalkyl-1H-imidazoles are poorly soluble in water, but can be dissolved in organic 
solvents. While a few of the studied compounds (MPV-207 AIV and MPV-295 AIV) have 
been used for research purposes only, others are currently used as pharmacologically 
active agents. The specific and selective α2-agonists detomidine and medetomidine are in 
veterinary use as analgesic sedatives (Vainio, 1988; Kuusela et al., 2000). While 
detomidine is used for horses, cattle and other large animals, medetomidine is used for 
smaller domestic animals such as the dog and the cat. Atipamezole is an antagonist of the 
α2-adrenoceptor, and as it rapidly reverses the sedation induced by detomidine or 
medetomidine, it is commonly used by veterinarians to awaken animals from sedation 
(Pertovaara et al., 2005).  
Dexmedetomidine [(+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole], the active 
enantiomer of the racemic medetomidine, is currently also in human use and displays 
sedative, analgesic, and anxiolytic effects after intravenous administration to postsurgical 
patients (Bhana et al., 2000). The other enantiomer, levomedetomidine [(–)-4-(R)-[1-(2,3-
dimethylphenyl)ethyl]-1H-imidazole], is practically devoid of pharmacological activity 
(Savola and Virtanen, 1991). The advantage of dexmedetomidine over other sedative 
agents in clinical use is that it produces rapid and stable sedation, while maintaining a high 
degree of patient rousability and anxiety reduction (Bhana et al., 2000). After a single 
intravenous dose to healthy volunteers, dexmedetomidine is rapidly distributed (t1⁄2α 9 
min) and eliminated with an elimination half-life of approximately 2 hours after extensive 
metabolism in the liver. Dexmedetomidine is metabolized across species via CYP-
mediated hydroxylations, followed by carboxylic acid or glucuronide formations (Salonen, 
1989; Salonen, 1991). However, in humans, direct glucuronidation at imidazole N3 and N1 
(Fig. 9) represents the major metabolic pathway (data in file). 
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Figure 9 Structures of the studied compounds. The N-glucuronidation site(s) is marked with an 
arrow and the major sites are indicated in boldface. Detomidine, atipamezole, MPV-
207 AIV, and MPV-295 AIV each produced one major N-glucuronide product in 
HLM, and the site of glucuronidation is tentative. 
2.5.2 Nicotine and cotinine 
Nicotine, a pyridine alkaloid (Fig. 9), is the addictive agent in tobacco products. The 
addictive properties are thought to result from increased dopamine levels in the brain 
(Benowitz, 2009). Nicotine addiction is the cause of continued use of tobacco products, 
which in turn results in exposure to the variety of carcinogenic nitroso compounds present 
in tobacco smoke, making tobacco the greatest preventable cause of death due to cancer. 
Therefore, a wide variety of products for nicotine replacement therapies are available in 
different formulations. Nicotine has also been studied as an active ingredient in 
experimental therapy for Parkinson’s disease, Alzheimer’s disease, and ulcerative colitis. 
As a free base, nicotine is a hygroscopic, oily liquid miscible in water. Nicotine readily 
forms salts, which are usually solid and highly water-soluble. Nicotine is optically active, 
and the nicotine in tobacco is largely the levorotary (S)-isomer, while only 0.1-0.6% of 
total nicotine content is made up of the less active (R)-nicotine. During smoking nicotine 
is rapidly absorbed from the alveoli of lungs, and peak concentrations in blood are 
observed at the completion of cigarette smoking (Hukkanen et al., 2005; Tutka et al., 
2005). The pKa of the weakly basic nicotine is ∼8.0, suggesting that the ionized form 
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prevails at physiological pH and also under acidic conditions such as in the GI tract. In its 
ionized form, the permeation of nicotine across membranes is rather poor, thus limiting 
the use of oral formulations in replacement therapies. Nicotine undergoes extensive first-
pass metabolism in the liver, which also limits its peroral use. In humans, the elimination 
half-life of nicotine is ∼2 h, and although 8-10% of nicotine is excreted unchanged in 
urine, the primary elimination pathway is hepatic metabolism. The major metabolites of 
nicotine are cotinine (75%), N’-oxide metabolite (4-7%), and a direct N-glucuronide (3-
5%) (Hukkanen et al., 2005; Tutka et al., 2005). Cotinine, a pharmacologically inactive 
metabolite, is formed in a two-step reaction, the first step catalyzed by CYP2A6 and the 
second by the cytosolic enzyme aldehyde oxidase. Before excretion, cotinine is 
extensively metabolized further, mainly to a direct N-glucuronide conjugate and to a 
hydroxyl metabolite.  
Large interspecies differences in the direct N-glucuronidation of nicotine have been 
observed (Ghosheh and Hawes, 2002a). While HLM catalyzed nicotine N-glucuronidation 
efficiently, the glucuronidation rates in rhesus and cynomolgus monkey microsomes were 
only about 7-11% of the rates measured in HLM. Furthermore, only low levels of nicotine 
N-glucuronide were detected in mini-pig and guinea-pig microsomes, and glucuronidation 
rates were undetectable in rats, mice, dogs, and rabbits. However, marmoset monkey liver 
microsomes were reported to glucuronidate nicotine (Tsai and Gorrod, 1999). 
Glucuronidation of cotinine, the major metabolite of nicotine, was also efficiently 
catalyzed by HLM. Interestingly, cotinine N-glucuronide was not detected in any of the 
above-mentioned animal species (Tsai and Gorrod, 1999; Ghosheh and Hawes, 2002a). 
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3. Aims of the study 
Many nitrogen-containing drugs are cleared from the body predominantly as direct N-
glucuronide conjugates, without requiring CYP enzymes. N-Glucuronidation, a reaction 
catalyzed by a family of UGT enzymes, is nonetheless an under-examined pathway. The 
goals of this study were to evaluate, using different in vitro techniques, interspecies 
differences in N-glucuronidation and to elucidate which human UGT enzymes catalyze 
this reaction. 
  
More specifically, the aims were as follows: 
 
1. To develop liquid chromatographic methods to detect low levels of N-glucuronide 
conjugates formed in in vitro experiments. 
2. To examine interspecies differences in the N-glucuronidation of a set of 4-arylalkyl-
1H-imidazole substrates, such as medetomidine, using human and animal liver 
microsomes.  
3. To elucidate which human UGT enzymes are responsible for the N-glucuronidation of 
medetomidine enantiomers using a set of 16 recombinant UGT enzymes. 
4. To investigate the regio- and stereoselective N-glucuronidation of medetomidine by 
performing detailed enzyme kinetics experiments. 
5. To evaluate which UGT enzymes contribute to the N-glucuronidation of nicotine and 
its major metabolite cotinine in the human liver. 
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4. Materials and methods 
4.1 Chemicals 
Chemical structures of the substrates and their N-glucuronidation site(s) are presented in 
Fig. 9. 4-Arylalkyl-1H-imidazoles dexmedetomidine (II, IV), levomedetomidine (I, II, 
IV), 3H-levomedetomidine (I, II), detomidine (II), atipamezole (II), MPV-207 AIV (II), 
and MPV-295 AIV (II) were kindly provided by Orion Pharma (Espoo, Finland). (S)-(-)-
Nicotine (III) and (S)-(-)-cotinine (III) were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). Metabolite standards nicotine-N-β-glucuronide (NG) and cotinine-N-β-D-
glucuronide (CG), and internal standards nicotine-N-β-glucuronide(-methyl-d3) and (R,S)-
cotinine-N-β-D-glucuronide(-methyl-d3) were purchased from Toronto Research 
Chemicals (Toronto, ON, Canada). UDPGA was obtained from Roche Molecular 
Biochemicals (Mannheim, Germany) (I, II) or Fluka Chemie (Buchs, Switzerland) (III, 
IV), while 14C-UDPGA [glucuronyl-14C(U)] (I, II, IV) was from Perkin Elmer Life 
Sciences (Boston, MA, USA). Other chemicals were mainly from Sigma-Aldrich and 
were of the highest purity available. 
4.2 Tissue microsomes 
Human and animal liver microsomes and human intestine microsomes (HIM) used in the 
studies are listed in Table 4. Preparation of noncommercial microsome batches are 
described in detail in the original publications.  
 
Table 4 Characteristics of human and animal tissue microsomes. 
Microsome preparation Sex and pool size Supplier Publication 
Human liver  Unknown Human Biologics, Scottsdale, AZ, USA I, II 
Human liver Mixed; n=18-30 BD Biosciences, San Jose, CA, USA  III, IV 
Human intestine Mixed; n=5 BD Biosciences III, IV 
Rat liver (Wistar) Male; n=6 Finnish Institute of Occupational Health, 
Helsinki, Finland 
II 
Rat liver (Wistar Han) Male; n=20 BD Biosciences IV 
Dog liver Male; n=1 Orion Pharma, Turku, Finland II 
Dog liver Male; n=2 Orion Pharma, Espoo, Finland IV 
Mouse liver (CD-1) Male; n=3 Orion Pharma, Espoo, Finland IV 
Guine-pig liver Unknown Orion Pharma, Espoo, Finland IV 
Rabbit liver Male; n=1 Orion Pharma, Espoo, Finland IV 
Mini-pig liver (Gottingen) Male; n=3 BD Biosciences IV 
Monkey liver (Cynomolgus) Male; n=6 BD Biosciences IV 
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4.3 Recombinant human UGTs 
Recombinant human UGTs used in the studies are listed in Table 5. Recombinant 
UGT1A6 and UGT1A9 used in study II were produced as detailed previously (Forsman et 
al., 2000). Recombinant UGT enzymes used in studies III and IV were produced as 
described earlier (Kurkela et al., 2003; Kurkela et al., 2007), and their relative expression 
levels were determined, side by side, by immunodetection using the tetra-His monoclonal 
antibody (QIAGEN GmbH, Hilden, Germany) as detailed elsewhere (Kurkela et al., 
2007). 
 
Table 5  Recombinant human UGTs used in the studies.  
Human UGT Expression system Supplier Publication 
UGT1A3 Baculovirus-infected SF-9 insect cells Panvera, Madison, WI, USA II 
UGT1A4 AHH-1 cells  Gentest, Woburn, MA, USA II 
UGT1A6  Semliki Forest virus-infected V79 cells University of Helsinki, Finland II 
UGT1A9 “ “ II 
UGT1A1 Baculovirus-infected SF-9 insect cells University of Helsinki, Finland IV 
UGT1A3 “ “ IV 
UGT1A4 “ “ III, IV 
UGT1A5 “ “ IV 
UGT1A6 “ “ IV 
UGT1A7 “ “ IV 
UGT1A8 “ “ IV 
UGT1A9 “ “ III, IV 
UGT1A10 “ “ IV 
UGT2B4 “ “ IV 
UGT2B7 “ “ III, IV 
UGT2B10 “ “ III, IV 
UGT2B11 “ “ IV 
UGT2B15 “ “ IV 
UGT2B17 “ “ IV 
UGT2B28 “ “ IV 
4.4 mRNA expression of UGT enzymes in human tissues 
Gene expression levels of UGT1A4, UGT2B7, and UGT2B10 in selected human tissues 
(liver, kidney, stomach, small intestine, colon, trachea, lung, and brain) were determined 
using a quantitative RT-PCR method as detailed in publication III.  
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4.5 In vitro glucuronidation assays 
4.5.1 Glucuronidation screens 
The incubation mixtures for the initial screens contained 100 mM phosphate buffer pH 
7.4, 5 mM MgCl2, 5 mM UDPGA, and mainly 0.5 mM substrate in a total volume of 100 
µl. Liver and intestine microsome incubates usually contained 0.2-0.5 mg microsomal 
protein per ml. Incubates of recombinant human UGTs, which were used either as cell 
homogenates or microsomal membranes, contained 1-3 mg protein per ml. Stock solutions 
(10-50 mM) of the substrates were prepared in water, provided that the water solubility of 
the substrate was adequate, or in organic solvent (dimethyl sulfoxide or methanol). As a 
result, the final incubates of some substrates contained up to 5% organic solvent. 
However, these amounts of organic solvents were found to inhibit each reaction by less 
than 10%. Consumption of the substrate was kept at <10% during the incubations. Triton 
X-100 (I, II) or alamethicin (III, IV) was added to liver and intestine microsome incubates 
to activate the glucuronidation reactions, but was not added to incubations with 
recombinant UGTs. Saccharolactone, the inhibitor of β-glucuronidase, was omitted since 
it slightly inhibited some glucuronidation reactions, as also reported by Olesen and Court 
(2008). The reactions were initiated by the addition of UDPGA and incubated at 37°C for 
60 or 120 min. The reactions were terminated by protein precipitation. A mixture of 
methanol and perchloric acid was used for protein precipitation in the 4-arylalkyl-1H-
imidazole samples, while trifluoroacetic acid was used in the nicotine and cotinine 
samples. Preliminary tests were performed to show that the formed glucuronide conjugates 
were stable in the samples after terminating the reactions. After centrifugation, the 
supernatants were analyzed by liquid chromatography. Further details of the incubations 
are presented in the original publications. 
4.5.2 Optimization of incubation conditions 
Before detailed kinetic assays, some preliminary tests were conducted to determine the 
optimal incubation conditions. Firstly, the effect of different incubation buffers adjusted to 
different pH values was evaluated using atipamezole as a test substrate. Atipamezole was 
incubated with HLM and recombinant human UGT1A4 in the following conditions: 
100 mM sodium acetate buffer pH 4.5, 5.0, 5.5, and 5.8; 100 mM sodium phosphate 
buffer pH 6.2, 6.5, 6.8, 7.0, 7.2, and 7.4; and Tris buffer pH 7.4, 8.0, 8.5, and 9.0. 
Secondly, the effect of the latency-disrupting agents Triton X-100 and alamethicin was 
tested using dexmedetomidine as a test substrate. Dexmedetomidine was incubated with 
HLM and recombinant human UGT1A4 using Triton X-100, at concentrations of 0.05, 
0.1, 0.2, 0.3, 0.4, and 0.5 mg per mg protein, and alamethicin, at concentrations of 12.5, 
25, 37.5, 50, and 62.5 μg per mg protein. Finally, since in preliminary experiments the 
activity of recombinant human UGT2B10 was noted to decline during the isolation of 
50 
 
 
 
 
microsomal membranes from the cells, the rate of nicotine glucuronidation by UGT2B10 
and also by UGT1A4 was tested using both microsomal membranes and lysed cell 
homogenates.  
4.5.3 Kinetic assays 
The incubation mixtures for kinetic assays by human and dog liver microsomes and 
recombinant human UGTs were prepared essentially as described in “Glucuronidation 
screens”, typically using 10 different substrate concentrations and 2-4 replicate incubates. 
Each reaction was performed under conditions where glucuronide formation was found to 
be linear with respect to incubation time and protein concentration. Incubation conditions 
are summarized in Table 6.  
 
Table 6  Incubation conditions of kinetic assays.  
Substrate                       
(and possible solvent) 
S 
 
(µM) 
Enzyme 
preparate 
Protein 
concentration 
(mg/ml) 
Triton 
 
(µg/ml) 
Alamethicin 
 
(µg/ml) 
Incubation 
time 
(min) 
II       
Dexmedetomidineb 2-3500 HLM 0.2 50 - 45 
 20-5000 DLMa 0.2-0.3 0 - 45 
Levomedetomidineb  2-500 HLM 0.1 50 - 45 
 20-3500 DLM 0.2 0 - 45 
Detomidineb 5-1000 HLM 0.1 50 - 60 
 100-10000 DLM 0.3 0 - 45 
Atipamezoleb 0.2-30 HLM 0.1 50 - 45 
 50-3000 DLM 0.3 0 - 45 
MPV-207 AIV  
(5% methanol) 
2.5-1000 HLM 0.1 50 - 20 
 50-5000 DLM 0.2 50 - 45 
MPV-295 AIV 2.5-1000 HLM 0.1 50 - 45 
 20-5000 DLM 0.1 25 - 45 
III       
Nicotine 5-4000 HLM 0.2 - 20 60 
 5-4000 UGT1A4 1 - - 120 
 5-4000 UGT2B10 1 - - 60-120 
Cotinine 5-4000 HLM 0.2 - 20 60 
 5-4000 UGT1A4 1 - - 120 
 5-4000 UGT2B10 1 - - 120 
IV       
Dexmedetomidineb 2.5-2000 HLM 0.2 - 20 60 
 2.5-2000 UGT1A4 1 - - 120 
 2.5-2000 UGT2B10 1 - - 240 
Levomedetomidinec 2.5-2000 HLM 0.2 - 20 30 
(≤4% methanol) 2.5-2000 UGT1A4 2 - - 120 
 2.5-2000 UGT2B10 1 - - 120 
aDLM = dog liver microsomes; bused as hydrochloride salt; cused as free base 
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4.6 Liquid chromatography  
The analytical methods and equipment used in the studies are listed in Table 7.  
 
Table 7 Liquid chromatographic methods used in the study.  
Substrate tR of 
glucuronid
e (min) 
LC Column and  
column oven 
temperature 
Eluent and  
flow rate 
Detector(s) 
I and II      
Atipamezole  
Detomidine  
Dexmedetomidine  
 
Levomedetomidine  
 
MPV-207 AIV  
MPV-295 AIV 
7.2 
4.8 
7.0 (DG1)  
9.0 (DG2) 
6.5 (LG1)  
9.0 (LG2) 
4.7 
6.6 
Agilent1100 a  
 
Symmetry C18 
150×3.9 mmb 
40° 
NaH2PO4 
pH 3.0  
(50 mM)  
and   
methanol  
(68:32) 
1 ml/min  
UV 215 nm 
and 
Model 9701 
FSAc 
I and II 
3H-Levomedetomidine 
6.5 (LG1) Agilent 1090 Symmetry C18 
150×3.9 mm 
40° 
 
   “ 
Model 150TR 
FSAd 
III      
Nicotine 
Cotinine 
6.3 
8.3 
Agilent 1100 Discovery C18 
HS F5e 
100×2.1 mm 
30°  
Trifluoroacetic 
acid  pH 2.2 
and  methanol.  
A linear 15-
min gradient 
from 5%  to 
30% methanol  
0.2 ml/min 
Model  
G-1946A MS, 
Agilentf  
 IV      
Dexmedetomidine 
 
Levomedetomidine 
 
7.0 (DG1) 
9.0 (DG2)  
6.5 (LG1) 
9.1 (LG2) 
Agilent 1100 Symmetry C18 
150×3.9 mm 
30° 
NaH2PO4 
pH 3.0  
(50 mM)  
and   
methanol  
(62:38) 
1 ml/min  
UV 215 nm 
and  
Model 500TR 
FSAg 
aAgilent Technologies, Waldbronn, Germany 
bWaters, Milford, MA, USA 
cReeve Analytical, Glasgow, UK. The flow scintillation analyzer was equipped with a heterogeneous 200-µl 
flow cell packed with silanized cerium-activated lithium glass (GS1/TSX).  
dPackard, Meriden, CT, USA. The flow scintillation analyzer was equipped with a homogeneous 500-µl 
flow cell. Monoflow 3 scintillation fluid (National Diagnostics, Atlanta, GA, USA) was used at 3 ml/min.  
eSigma-Aldrich, St. Louis, MO, USA 
fNG and CG were detected as MH+ ions at m/z 339 and 353, respectively, and their methyl-d3-glucuronides 
were used as internal standards. 
gPerkin Elmer Life Sciences, Waltham, MA, USA. The flow scintillation analyzer was equipped with a 0.5-
ml flow cell. Ultima-Flo (Perkin Elmer Life Sciences) scintillation liquid was used at 3 ml/min. 
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4.6.1 Methods utilizing 14C-UDP-glucuronic acid (UDPGA) (I, II, IV) 
Glucuronide conjugates of 4-arylalkyl-1H-imidazoles formed in the in vitro incubates 
were analyzed using LC coupled with a UV detector and a flow scintillation analyzer as 
detailed in publication I. Briefly, along with the actual incubates, separate quantitation 
samples were prepared and incubated essentially as described in “Glucuronidation 
screens”, using HLM as the enzyme source. Unlike the actual samples, the quantitation 
samples were incubated in the presence of both 14C-UDPGA (3.7-14.8 kBq) and 
nonradiolabeled UDPGA (0.02-0.5 mM). The glucuronides formed in these quantitation 
samples were then monitored using both the UV and FSA detector equipped with either a 
heterogeneous or homogeneous flow cell (Table 7). Thereafter, using the data obtained 
from the quantitation samples by the FSA detector, a calibration curve was constructed for 
the UV detector [glucuronide (pmol) vs. UV peak area (mAU×s)], and the UV detector 
was subsequently used to quantify the glucuronides formed in the actual samples 
incubated only with nonradiolabeled UDPGA.  
4.6.2 Methods utilizing 3H-levomedetomidine (I, II) 
Levomedetomidine glucuronidation by HLM in studies I and II was quantified by adding 
3H-levomedetomidine (18.5-55.5 MBq) to the “Glucuronidation screens” incubation 
mixture as detailed in publication I. The glucuronides formed were monitored using LC – 
FSA equipped with a heterogeneous flow cell (Table 7).   
4.6.3 Liquid chromatography – mass spectrometry (LC-MS) (III) 
Glucuronide conjugates of nicotine and cotinine in the in vitro incubates were analyzed 
using LC coupled with a single quadrupole mass spectrometer with atmospheric pressure 
electrospray ionization (Table 7). Authentic glucuronide standards and their methyl-d3-
derivatives as internal standards were used for quantitation by comparing peak area ratios 
(analyte/internal standard) to the peak area ratios generated with a standard curve. Further 
details can be found in publication III. 
4.7 Enzyme kinetics analyses 
The enzyme kinetic parameters were estimated by nonlinear regression analysis using 
Leonora enzyme kinetics program version 1.0 (Cornish-Bowden, 1995) (I, II), or 
SigmaPlot enzyme kinetics module version 1.1 (SPSS Inc., Chicago, IL, USA) (III, IV). 
The initial reaction velocity data were fitted to enzyme kinetics equations (1) – (4) 
described in Section 2.4.5 using appropriate weighting factors. Goodness-of-fit to the 
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equations was evaluated by visual inspection of the Michaelis-Menten, Eadie-Hofstee, and 
residual plots, the standard errors of the parameters, and R2 values. 
4.8 Prediction of hepatic clearance via glucuronidation 
Hepatic clearances were estimated from human liver microsomal data using equations (5) 
– (10)  described in Section 2.4.6 and the parameters presented in Tables 8 and 9. 
 
Table 8 Scaling factors used for CL predictions of human liver microsomal data. 
Parameter Value Reference 
MPPGL 32 mg per gram liver  Barter et al., 2007  
wL 25.7 g liver per kg body weight  Davies and Morris, 1993  
QH 20.7 ml per min per kg body weight  Davies and Morris, 1993  
 
Table 9 Drug-dependent parameters used for CL predictions of human liver microsomal 
data. References are presented in parentheses. 
Parameter Dexmedetomidine Nicotine 
fu,p 0.06a  0.95 (Hukkanen et al., 2005) 
RB 0.72a 1.00b 
fu,b 0.083 0.95 
fu, in vitro 0.50 (Toivonen, 2007) 1.00 (Toivonen, 2007) 
aunpublished observation, Orion Pharma Study Report 
bassumption; value not available 
4.9 Biosynthesis and nuclear magnetic resonance (NMR) 
analyses of dex- and levomedetomidine glucuronides 
Dexmedetomidine glucuronides DG1 and DG2, and levomedetomidine glucuronide LG1 
were prepared using biosynthesis catalyzed by HLM, as described in detail in publication 
IV. The regioisomeric glucuronides were separated using SPE followed by fraction 
collection by LC. The final glucuronide products were lyophilized. One-dimensional and 
two-dimensional NOESY 1H NMR spectra of the glucuronide samples dissolved in D2O 
were recorded using a Varian Unity INOVA 600 MHz spectrometer (Varian, Inc., Palo 
Alto, CA, USA). 
5. Results 
5.1 Analytical methods 
5.1.1 Methods utilizing 14C-UDPGA (I, II, IV) 
4-Arylalkyl-1H-imidazole glucuronides were analyzed by LC using a UV detector in 
series with FSA (Table 7), as detailed in Section 4.6.1. Typical LC-UV-FSA 
chromatograms of the separation of dexmedetomidine and its regioisomeric glucuronides 
DG1 and DG2 are presented in Fig. 10. Retention times of the different 4-arylalkyl-1H-
imidazole glucuronides were between 4.8 min and 9.1 min (Table 7), whereas the 
aglycone substrates eluted between 10 min and 14 min. This “two-detector method” was 
found to be more sensitive (detection limit ~5-10 pmol) than the FSA alone (detection 
limit ~100–200 pmol according to Coughtrie et al., 1986). 
UDPGA                                    DG1           DG2                  Dexmedetomidine
min
min
dpm
mAU
 
Figure 10 Detection of dexmedetomidine glucuronidation by LC using UV detection (above) and 
flow scintillation analyzer (below). The chromatograms demonstrate the detection of 
DG1 and DG2 produced by incubation of dexmedetomidine (0.5 mM) with HLM.  
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5.1.2 Methods utilizing 3H-levomedetomidine (I, II) 
Along with the method utilizing 14C-UDPGA, a method utilizing 3H-labeled aglycone 
substrate was developed for the levomedetomidine glucuronidation experiments. 3H-
levomedetomidine was added to the in vitro incubates and the glucuronides formed were 
analyzed by LC-FSA (Table 7). This method was found to be highly applicable for in vitro 
kinetic assays. Since the relative proportion of the radiolabel was higher, this method was 
more sensitive than the method utilizing 14C-UDPGA. The limitation of this method is that 
radiolabeled substrates are rarely available, whereas the method utilizing 14C-UDPGA can 
be used universally. 
5.1.3 LC-MS (III) 
Nicotine and cotinine glucuronides were analyzed by LC-MS using authentic glucuronide 
standards and their methyl-d3-derivatives as internal standards. Typical LC-MS 
chromatograms of nicotine and cotinine incubations with human UGT1A4 and UGT2B10 
are presented in Fig. 11. Separation of the glucuronides from the unreacted aglycone 
substrates was performed using a novel pentafluorophenylpropyl-bonded column and a 
trifluoroacetic acid – methanol gradient (Table 7). Good retention was obtained for these 
highly hydrophilic glucuronides, which have very poor retention by conventional C18 
columns. The retention times of nicotine and cotinine glucuronides were approximately 
6.3 and 8.3 min, respectively, whereas their aglycone substrates eluted between 11 min 
and 13 min. In the course of the study, the retention times of the glucuronides were not 
constant (variation at least ± 1 min between batches), probably due to instability of the 
column used. However, quantitation was reliable, as the internal standards always eluted 
at the same retention time as the respective glucuronides. The limit of detection was 0.5 or 
1.0 pmol for NG and CG, respectively, showing a clearly improved sensitivity over the 
LC-UV-FSA system used for 4-arylalkyl-1H-imidazole glucuronides. The limitation of 
this method is that authentic glucuronide standards as well as respective internal standards 
are needed for reliable quantitation by MS.  
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Figure 11 LC-MS chromatograms of nicotine (A) or cotinine (B) (0.5 mM) incubation with 
human UGT1A4 or UGT2B10. NG and CG were detected as MH+ ions at m/z 339 
and 353, respectively. 
5.2 Biosynthesis and structural characterization of dex- and 
levomedetomidine glucuronides (IV) 
The 4-arylalkyl-1H-imidazoles investigated are subject to glucuronidation at the two 
imidazole ring nitrogens, N1 and N3 (Fig. 9). Accordingly, when dexmedetomidine was 
incubated with HLM, two N-glucuronide products were detected in the respective LC-UV 
chromatogram (Fig. 10). The peak area ratio of these two regioisomeric glucuronides 
(“G1:G2”) was ~4:1. However, when the other 4-arylalkyl-1H-imidazoles (Fig. 9) were 
incubated with HLM, primarily one glucuronide product, named “G1” according to the 
elution order, was formed, while the formation of the later eluting glucuronide, “G2”, was 
negligible (<5%). The G1 and G2 peaks were isolated from the HLM incubates of dex- 
and levomedetomidine and analyzed by LC-MS. An MH+ ion at m/z 377 was observed in 
all four samples, indicating the formation of two regioisomeric monoglucuronides from 
both dex- and levomedetomidine by HLM.  
For further structural characterization, dex- and levomedetomidine regiomeric 
glucuronides were produced using biosynthesis by HLM, and the purified, lyophilized  
regioisomers were subjected to NMR analyses (IV). The samples for NMR contained 
0.25 mg DG1, 0.13 mg DG2, or 1.6 mg LG1. The LG1 sample contained ~5% of 
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levomedetomidine N1-glucuronide (LG2) as an “impurity” since it was considered 
unnecessary to separate these regioisomers after the HLM incubation due to the low 
relative proportion of LG2.  
Inter-glycosidic NOE correlations indicated that DG1 and DG2 are the N3- and N1-
glucuronides of dexmedetomidine, respectively, and LG1 is the N3-glucuronide of 
levomedetomidine. Thus, N3 was shown to be the preferred glucuronidation site of these 
4-arylalkyl-1H-imidazoles, at least in the cases of dex- and levomedetomidine. The 
proposed 3D structures of the glucuronides are presented in Fig. 12.  
DG1
DG2
LG1  
Figure 12 Proposed structures of DG1 (N3-glucuronide of dexmedetomidine); DG2 (N1-
glucuronide of dexmedetomidine); and LG1 (N3-glucuronide of levomedetomidine) 
based on experimental 1D and 2D NMR data. Key NOE correlations used in the 
identification of the different glucuronides are indicated by dashed lines. All 
distances between correlating protons are smaller than 5Å in the depicted structures. 
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5.3 N-Glucuronidation by human and animal tissue 
microsomes 
5.3.1 4-Arylalkyl-1H-imidazoles (II, IV) 
Differences across species in the N-glucuronidation of 4-arylalkyl-1H-imidazoles were 
investigated using dex- and levomedetomidine as model substrates. Human and animal 
liver microsomes were incubated with the model substrates using a 0.5 mM substrate 
concentration, and the formation of the stereo-/regioisomeric glucuronides DG1, DG2, 
LG1, and LG2 was analyzed. HLM catalyzed the glucuronidation of dex- and 
levomedetomidine more actively than the liver microsomes of any other species (Table 
10). Besides HLM, only dog liver microsomes glucuronidated medetomidine at 
considerable rates. Human intestine microsomes were also tested, and they catalyzed the 
N-glucuronidation of medetomidine at a very low rate, only 0.1-2% of the rate found in 
HLM.  
 
Table 10 N-Glucuronidation of the compounds studied by human and animal liver 
microsomes and by human intestine microsomes.  
The substrate concentration in the assays was 0.5 mM. Activities were measured in duplicate (<15% 
difference), and mean data are presented. Note that while the same batch of HLM was used for all substrates, 
the batch of HIM used for dex-and levomedetomidine incubations was different from the batch used for 
nicotine and cotinine incubations; thus the HIM results are not directly comparable.  
 
  
Human 
liver 
Human 
intestine 
Rat 
liver 
Mouse
liver 
Guinea-pig 
liver 
Rabbit 
liver 
Dog 
liver 
Mini-pig 
liver 
Monkey
liver 
 UGT activity (pmol/min/mg) 
Dexmedetomidine          
DG1 801 11 1.1 N.D. 13 2.1 108 1.2 3.9 
DG2 185 2.2 2.0 N.D. 11 1.3 8.6 N.D. 38 
Levomedetomidine          
LG1 1410 N.D. N.D. N.D. 15 N.D. 381 N.D. 2.8 
LG2 67 1.6 5.8 N.D. 5.0 N.D. N.D. N.D. 19 
Nicotine 220 0.077 N.M. N.M. N.M. N.M. N.M. N.M. N.M. 
Cotinine 108 N.D. N.M. N.M. N.M. N.M. N.M. N.M. N.M. 
N.D. = activity below quantification limit (0.2 pmol/min/mg for DG1, DG2, LG1, and LG2, and 0.04 and 
0.08 pmol/min/mg for NG and CG, respectively).  
N.M. = not measured 
 
HLM catalyzed the N-glucuronidation of dex- and levomedetomidine regioselectively, 
and N3-glucuronide (i.e. DG1 or LG1) was the prevailing product (Table 10). Especially 
levomedetomidine conjugation by HLM was highly regioselective, producing 95% LG1, 
while 80% DG1 was formed from dexmedetomidine. Essentially similar high preference 
for the G1 regioisomer formation (>95% G1) was seen with the other 4-arylalkyl-1H-
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imidazole substrates, including atipamezole (unpublished observation). In these cases, the 
site of glucuronidation (N3 or N1) was not characterized by NMR analyses. It is, however, 
tempting to suggest based on the structural characterization of dex- and levomedetomidine 
glucuronides that also other 4-arylalkyl-1H-imidazoles investigated are preferentially 
glucuronidated at N3 (Fig. 9). Also dog liver microsomes preferentially catalyzed the 
formation of DG1 and LG1, while the regioselectivity of Cynomolgus monkey liver 
microsomes was different, as relatively much more of each G2 glucuronide was formed 
and only low levels of DG1 and LG1 were detected.  
5.3.2 Nicotine and cotinine (III) 
The N-glucuronidation of nicotine and cotinine was screened only in human liver and 
intestine microsomes. HLM catalyzed nicotine and cotinine glucuronidation at moderate 
rates; the rates were, however, lower than those measured for dex- and levomedetomidine 
glucuronidation (Table 10). HIM catalyzed nicotine glucuronidation at a very low rate, 
which was only ∼0.1% of the rate found in the liver. Cotinine glucuronidation by HIM 
was not detected. 
5.4 N-Glucuronidation by recombinant human UGTs  
5.4.1 4-Arylalkyl-1H-imidazoles (II, IV) 
In the first set of experiments (study II), N-glucuronidation activity of human recombinant 
UGTs 1A3, 1A4, 1A6, and 1A9 towards medetomidine enantiomers and atipamezole was 
tested. Only UGT1A4 catalyzed the N-glucuronidation of these substrates, and the 
observed activities were low (II: Table 2). In the same experiment, UGT1A4 was shown to 
efficiently catalyze the N-glucuronidation of 4-aminobiphenyl, a known substrate of 
UGT1A4 (Green and Tephly, 1996). In fact, 4-aminobiphenyl glucuronidation rate by 
UGT1A4 was 25-fold that of levomedetomidine, whereas the difference in the Vmax values 
of levomedetomidine and 4-aminobiphenyl glucuronidation by HLM was much smaller 
(1.89 vs. 5.07 nmol/min/mg) (II: Table 1). These results indicated that, in addition to 
UGT1A4, another UGT isoenzyme(s) contributes to the glucuronidation of medetomidine 
and other 4-arylalkyl-1H-imidazoles in the human liver. 
In the search for the “missing” UGT, a set of recombinant UGTs encoding two 
different UGT enzymes simultaneously was prepared (unpublished data). Based on 
previous findings from the coexpression of different UGTs (Kurkela et al., 2007), it was 
speculated that hetero-oligomerization of UGT1A4 with another UGT enzyme could 
stimulate the activity of UGT1A4 to the level observed in HLM. The glucuronidation 
experiments were performed using lysed cell homogenate preparates, and the usual step of 
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isolating the microsomal membranes was skipped. When levomedetomidine (50 µM) was 
incubated with cells coinfected with UGT1A4 and UGT2B10, the formation of LG1 was 
unexpectedly observed to be 10 times more efficient than in any other coinfection sample. 
Moreover, a high preference for LG1 formation (97%) was observed in this 
“UGT1A4+UGT2B10” sample, while in all other samples the relative proportion of LG1 
was ~80%. This finding indicated that UGT2B10, either alone or as a hetero-oligomer 
with UGT1A4, could catalyze the N-glucuronidation of the compounds investigated.  
Sixteen recombinant human UGT enzymes, including the newly discovered 
UGT2B10, were then tested for their ability to catalyze the N-glucuronidation of dex- and 
levomedetomidine. Recombinant UGTs were used as cell homogenates since preliminary 
experiments showed that the activity of UGT2B10 declined upon the isolation of 
microsomal membranes, as detailed in Section 5.6.3. Four different human UGTs, namely 
1A3, 1A4, 2B7, and 2B10, catalyzed to different degrees the N-glucuronidation of 
medetomidine enantiomers (Fig. 13). The highest (normalized) activity towards 
dexmedetomidine was exhibited by UGT1A4, while lower activities were observed with 
the three other enzymes, in the order UGT2B10 >> UGT1A3 ≈ UGT2B7. In the case of 
levomedetomidine, the highest glucuronidation rate was measured with UGT2B10, 
whereas the activities of the other UGTs were considerably lower. Thus, according to the 
first screen against 16 human UGTs, UGT1A4 and UGT2B10 in particular seemed to play 
a major role in medetomidine glucuronidation, while the contributions of UGTs 1A3 and 
2B7 were minor. 
Levomedetomidine glucuronidation by UGT2B10 was highly regioselective, as only 
LG1 was formed (Fig. 13). On the contrary, UGT1A4 produced both LG1 and LG2 in a 
ratio of 2:1. In the case of dexmedetomidine, UGT1A4 showed a preference for DG1 
formation (87%), while UGT2B10 activity showed no significant regioselectivity. N-
Glucuronidation of atipamezole, another 4-arlylalkyl-1H-imidazole, by UGT2B10 
produced only the G1 glucuronide, whereas both G1 and G2 were formed by UGT1A4 at 
a low rate (unpublished observation).  
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Figure 13 N-Glucuronidation of studied compounds by human recombinant UGTs. The activity 
values are directly comparable, as they are normalized to the expression level of each 
UGT batch. 
The substrate concentration in the assays was 0.5 mM. Dex- and levomedetomidine N-glucuronidation by 
UGTs 1A1, 1A5, 1A6-1A10, 2B4, 2B11, 2B15, 2B17, and 2B28 was also tested, but no activity was 
observed. Nicotine and cotinine N-glucuronidation by UGT1A9 was also assayed, but no activity was 
observed.  Activities were measured in duplicate (<15% difference), and the mean data are presented. The 
relative expression levels per milligram of protein in different UGT batches were 25.87, 1.96, 2.90, and 0.26 
for UGTs 1A3, 1A4, 2B7, and 2B10, respectively, when dex- and levomedetomidine glucuronidations were 
assayed, and 0.80, 1.51, and 1.56 for UGTs 1A4, 2B7, and 2B10 when nicotine and cotinine 
glucuronidations were assayed. 
5.4.2 Nicotine and cotinine (III) 
UGT1A4 and UGT1A9 were previously reported to catalyze nicotine glucuronidation 
(Kuehl and Murphy, 2003), although the measured activities were rather low. Also 
UGT2B7 was shown to catalyze some N-glucuronidation reactions (Zhang et al., 2004; Xu 
et al., 2006). Based on these findings, N-glucuronidation of nicotine and cotinine was 
screened using recombinant human UGT1A4, UGT1A9, and UGT2B7, along with 
UGT2B10. The glucuronidation experiments were conducted using cell homogenates to 
preserve the activity of UGT2B10 (see Section 5.6.3 for details). The results indicated 
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that, in terms of normalized activity, UGT2B10 is the most active human UGT in both 
nicotine and cotinine N-glucuronidation (Fig. 13). UGT1A4 catalyzed nicotine and 
cotinine N-glucuronidation at a lower but detectable rate. UGT1A9 showed no activity 
towards nicotine or cotinine, but a low level of nicotine glucuronidation by UGT2B7 was 
detected. Cotinine glucuronidation by UGT2B7 was not observed.  
5.5 mRNA expression of UGT enzymes in human tissues (III) 
The mRNA expression levels of three N-glucuronidating UGT enzymes, UGT1A4, 
UGT2B7, and UGT2B10, were determined in selected human tissues using a quantitative 
RT-PCR method. The levels of UGT1A4, UGT2B7, and UGT2B10 in the human liver 
were comparable (Fig. 14). The UGT2B10 gene was exclusively expressed, at least at the 
level of mRNA, in the liver, while it was not expressed, for example, in the small intestine 
(detection limit 0.05% of the liver level). UGT1A4 and UGT2B7, on the other hand, were 
expressed at significant levels in several other tissues, including the small intestine. These 
results are in good agreement, at least with respect to UGT2B7 and UGT2B10, with a 
recent report on the expression levels of 15 UGT enzymes in various human tissues (Ohno 
and Nakajin, 2009). However, compared with the results presented here, somewhat lower 
expression levels of UGT1A4 in the liver were reported by Ohno and Nakajin.  
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Figure 14 mRNA expression levels of N-glucuronidating enzymes in human tissues. 
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5.6 Optimization of incubation conditions for kinetic assays 
5.6.1 Choice of incubation buffer and pH (unpublished data) 
Atipamezole glucuronidation by HLM and human UGT1A4 was tested at 13 different pH 
values, ranging from 4.5 to 9.0. While both regioisomeric atipamezole glucuronides, G1 
and G2, were formed by UGT1A4, only G1 was formed by HLM. The relative 
glucuronidation rate of atipamezole was highest at pH 8.0 in both enzyme preparations 
(Fig. 15). However, the glucuronidation rates at pH 7.4 were only 10-30% lower than at 
pH 8.0. Glucuronidation of other 4-arylalkyl-1H-imidazoles, such as dex- and 
levomedetomidine, as a function of pH was highly similar to atipamezole (data not 
shown). Atipamezole N-glucuronidation rates were comparable in different incubation 
buffers, Tris or phosphate buffer pH 7.4. Based on these findings, phosphate buffer pH 7.4 
was used in subsequent kinetic assays. 
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Figure 15 Atipamezole N-glucuronidation by HLM and human UGT1A4 as a function of pH. 
Atipamezole concentration in the incubations was 50 µM (HLM) or 1 mM (UGT1A4). 
The formation rate of G2 was below the detection limit in all HLM samples.  
5.6.2 Latency-disrupting agents (II, IV) 
The effect of two commonly used latency-disrupting agents, the detergent Triton and the 
pore-forming peptide alamethicin, on dexmedetomidine glucuronidation by HLM and 
UGT1A4 was tested. Interestingly, Triton activated DG1 and DG2 formations in these 
enzyme preparations differently. Firstly, the optimal concentration of Triton (0.4 mg per 
mg protein) activated HLM-catalyzed DG2 formation sevenfold, while the activation of 
DG1 formation was only threefold (Fig. 16). Furthermore, while Triton activated DG2 
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formation by UGT1A4 about twofold, DG1 formation was significantly decreased already 
at the lowest concentrations of Triton. Alamethicin, on the other hand, activated both DG1 
and DG2 formations by HLM equally, about fourfold (IV: Fig. 3), and maximal activation 
was observed at an alamethicin concentration of ≥25 µg per mg protein. However, 
alamethicin had no effect, activation or inhibition, on dexmedetomidine glucuronidation 
by UGT1A4. As expected, the effect of Triton on dexmedetomidine glucuronidation was 
overall highly concentration-dependent, while the effect of alamethicin was constant after 
reaching the full activation. The use of alamethicin seemed therefore beneficial, and 
alamethicin was used in the kinetic assays of liver microsome incubations. As alamethicin 
did not activate glucuronidation by recombinant UGT preparations, it was not added to 
these incubates.  
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Figure 16 Effect of Triton on dexmedetomidine (0.5 mM) glucuronidation by HLM and 
recombinant human UGT1A4 (relative glucuronidation rate; rate without Triton = 
100%). 
5.6.3 Use and stability of different recombinant UGT preparations (III) 
Recombinant UGTs are generally used as microsomal preparates, as these enzymes are 
located within the endoplasmic reticulum of cells. Another option is to use insect cells as a 
lysed cell homogenate without isolation of microsomal membranes. When the UGT2B10 
cell homogenate was tested along with microsomal membranes prepared from the same 
UGT batch, the normalized levomedetomidine glucuronidation rate was almost fourfold 
higher in the cell homogenate than in the microsomal membrane (unpublished 
observation). In addition, a 2.5-fold higher glucuronidation rate in cell homogenate vs. 
microsomal membrane was detected when nicotine was used as the substrate (III: Fig. 3). 
This suggests that the activity of UGT2B10 declines with isolation of microsomal 
membranes and can partly explain why the N-glucuronidation activity of this enzyme has 
not been previously discovered. Furthermore, preliminary experiments indicate that the 
activity of UGT2B10 preparates decreases, at least to some extent, during storage at          
-80°C. In the case of UGT1A4, however, the normalized activities of cell homogenate and 
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microsomal membrane towards nicotine glucuronidation were very similar (III: Fig. 3). 
Therefore, UGT2B10 was used as a cell homogenate in further kinetic assays, while 
UGT1A4 incubations were conducted using either the cell homogenate or the microsomal 
membrane.  
5.7 Kinetic characterization of glucuronidation 
5.7.1 4-Arylalkyl-1H-imidazoles (II, IV) 
The glucuronidation screens revealed that N-glucuronides of 4-arylalkyl-1H-imidazoles 
were formed only in human and dog liver microsomes (Table 10). Therefore, detailed 
kinetic assays were performed using liver microsomes of these two species. HLM 
generally catalyzed these reactions much more efficiently than dog liver microsomes (II: 
Table 1). The apparent Km values for the formation of five different 4-arylalkyl-1H-
imidazole N-glucuronides by HLM, ranging from 4.0 µM (atipamezole) to 78 µM 
(detomidine), indicated rather high affinity. On the other hand, dog liver microsomes 
catalyzed the N-glucuronidation of 4-arylalkyl-1H-imidazoles at a rather poor affinity 
(apparent Km values between 279 µM and 1640 µM).  
Further kinetic characterization of dexmedetomidine glucuronidation by HLM 
indicated biphasic kinetics, strongly suggesting the involvement of two different UGTs in 
this reaction (Fig. 17). The apparent Km1 values (the high-affinity components) for DG1 
and DG2 formations by HLM were both below 10 µM, while the Km2 values (the low-
affinity components) were much higher, >1 mM (Table 11). The apparent Vmax values 
indicated a preference for DG1 formation. In the case of levomedetomidine, the kinetics of 
the prevailing regioisomer, LG1, by HLM was significantly different from LG2 formation. 
LG1 formation by HLM exhibited monophasic kinetics with a high affinity, Km 14 µM, 
along with substrate inhibition observed at high concentrations (Fig. 18, Table 11). LG2, 
by contrast, was formed by HLM at a low rate and at a poor affinity.  
When N-glucuronidation kinetics of dexmedetomidine by recombinant UGTs was 
assayed, large differences between UGT1A4 and UGT2B10 were observed. The affinity 
of UGT1A4 was low, Km 0.6-0.7 mM, for both DG1 and DG2 formation, but the 
normalized Vmax values, particularly in the case of DG1, were relatively high (Table 12). 
By contrast, UGT2B10 exhibited much higher affinity for dexmedetomidine, Km values 
between 10 µM and 20 µM for both DG1 and DG2 formations, but the normalized Vmax 
values were low. While the Vmax values observed with HLM and recombinant UGTs are 
not directly comparable, as the amounts of the UGT enzymes per mg protein in these 
preparates are not equal, comparison of Km values can be made. When the Km values of 
dexmedetomidine glucuronidation by HLM, UGT1A4, and UGT2B10 are compared, the 
Km values of UGT2B10 were very close to the high-affinity Km1s observed in HLM, while 
the Kms of UGT1A4 resembled the low-affinity Km2s in HLM (Tables 11 and 12). 
The kinetics of levomedetomidine N-glucuronidation by UGT2B10 highly resembled 
the kinetics observed in HLM (Fig. 18). Firstly, only N3-glucuronide (i.e. LG1) was 
formed, and, moreover, the reaction showed a high affinity, Km 7.4 µM, and a mild 
substrate inhibition (Table 12), which was the case also with HLM. By contrast, the 
affinity of UGT1A4 towards both LG1 and LG2 formations was rather poor. The 
normalized Vmax of UGT2B10 in LG1 formation was also considerably higher than that of 
UGT1A4.  
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Figure 17 Representative kinetic plots for dexmedetomidine N-glucuronidation by HLM (A; and 
Eadie-Hofstee plot; B); human UGT2B10 (C); and human UGT1A4 (D). 
The incubation conditions were as presented in Table 6. The glucuronidation rates represent the mean of two 
independent determinations, or the mean (±S.D.) of three independent determinations. The glucuronidation 
rates by recombinant UGTs presented here are not normalized according to the relative expression levels.  
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Figure 18 Representative kinetic plots for levomedetomidine N-glucuronidation by HLM (A; and 
Eadie-Hofstee plot; B); human UGT2B10 (C); and human UGT1A4 (D).  
The incubation conditions were as presented in Table 6. The glucuronidation rates represent the mean 
(±S.D.) of three of four independent determinations. The glucuronidation rates by recombinant UGTs 
presented here are not normalized according to the relative expression levels.  
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Table 11 Kinetic parameters for glucuronidation of studied compounds by HLM.  
The data are presented as mean ± standard error of parameter fit. 
  
 HLM 
 Km1  Km2  Vmax1  Vmax2  
 µM µM pmol/min/mg pmol/min/mg 
Dexmedetomidine     
DG1 a 6.61±1.10 1930±190 12±7 2290±140 
DG2a 8.73±1.23 1590±380 59.0±3.3  325 ± 43 
Levomedetomidine     
LG1 b 14.0±0.4  2150 ± 28  
LG2 c >1000  121 ± 15  
Nicotine 331±26  290±7  
Cotinine 1250±190  370±23  
aTwo-enzyme equation (Eq. 4, see Section 2.4.5) 
bSubstrate inhibition equation (Eq. 3), Ksi 860±30 µM; 
cKinetic constants could not be determined with confidence. In this case, the Vmax value indicates the highest 
observed glucuronidation rate at 2 mM substrate concentration. 
 
 
Table 12 Kinetic parameters for glucuronidation of studied compounds by human UGT1A4 
and UGT2B10.  
The data are presented as mean ± standard error of parameter fit.  
 
UGT1A4  UGT2B10 
 Km  Vmax Vmax  
(normal) a 
 Km Vmax Vmax 
(normal)a 
 µM pmol/min/mg  µM pmol/min/mg 
Dexmedetomidine   
DG1 644±132b 167±17 85.0±8.7  10.8±0.8 1.67±0.03 1.67±0.03
DG2 706±116 24.3±1.7 12.4±0.9  15.7±1.5 1.15±0.02 1.15±0.02
Levomedetomidine        
LG1 312±44 17.7±0.8 9.01±0.42  7.42±0.64c 29.3±0.8 29.3±0.8
LG2 1600±300 29.7±3.0 15.1±1.6  N.D.   
Nicotine 2420±360 3.99±0.30 0.302±0.023  288±15 3.30±0.05 3.30±0.05 
Cotinine 1540±200 14.9±0.8 1.13±0.06  1030±90 19.3±0.6 19.3±0.6 
N.D. = activity below quantification limit (0.2 pmol/min/mg for dex- and levomedetomidine, and 0.04 and 
0.08 pmol/min/mg for nicotine and cotinine, respectively).  
aNormalized Vmax values were calculated by dividing the Vmax value (pmol/min/mg) by the relative 
expression level of the UGTs. The relative expression levels of UGT1A4 cell homogenate used for levo-and 
dexmedetomide, UGT1A4 microsomal membrane used for nicotine and cotinine, and UGT2B10 cell 
homogenate used for all substrates were 1.96, 13.21, and 1.00, respectively. 
bHill equation (Eq. 2, see Section 2.4.5), n=1.25 
cSubstrate inhibition equation (Eq. 3), Ksi 1490±190 µM 
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5.7.2 Nicotine and cotinine (III) 
Kinetic assays of nicotine and cotinine N-glucuronidation indicated that HLM catalyzed 
nicotine glucuronidation at a higher affinity (Km 0.33 mM) than cotinine (Km 1.3 mM), 
while the Vmax values were comparable (Table 11). The observed kinetic parameters 
corresponded reasonably well with previously reported results (Ghosheh et al., 2001; 
Ghosheh and Hawes, 2002b; Nakajima et al., 2002c). When kinetic analyses were 
performed using recombinant human UGTs, the Km of UGT2B10 towards nicotine, 0.29 
mM, was very similar to the value observed in HLM, while the affinity of UGT1A4 was 
markedly lower (2.4 mM) (Table 12). In the case of cotinine glucuronidation, the Km 
values of UGT1A4, UGT2B10, and HLM were all close to each other (1.0-1.5 mM). 
Despite this, the expression-normalized Vmax of recombinant UGT2B10 in cotinine 
glucuronidation was significantly higher than that of UGT1A4.  
5.8 Estimates of hepatic clearance via glucuronidation 
(unpublished data) 
The kinetic data obtained from dexmedetomidine and nicotine glucuronidation 
experiments by HLM (Table 11) were used for in vitro – in vivo scaling. The estimates of 
intrinsic clearances, CLint, in vitro (i.e. Vmax/Km ratios), and hepatic clearances via 
glucuronidation, CLH, gluc, are presented in Table 13.  In the case of dexmedetomidine, the 
estimated intrinsic clearances for DG1 and DG2 formations by the high-affinity 
component (catalyzed by UGT2B10) were at least tenfold those of the low-affinity 
component (catalyzed by UGT1A4) indicating that UGT2B10 is mostly responsible for 
the hepatic glucuronidation of dexmedetomidine. The calculated CLH, gluc of 
dexmedetomidine was 24% of the observed in vivo clearance in blood (12.5 ml/min/kg) 
(data in file), whereas in the case of nicotine the calculated CLH, gluc was ~5% of the total 
clearance (14.5 ml/min/kg) (Hukkanen et al., 2005). These estimates correlate well with 
the in vivo situation since it has been reported that 3-5% of nicotine is eliminated as a 
direct glucuronide conjugate (Hukkanen et al., 2005), while 30-40% of dexmedetomidine 
has been estimated to be excreted in human urine as N3- and N1-glucuronides (data in file).   
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Table 13 Estimated hepatic clearances via glucuronidation, CLH, gluc, for dexmedetomidine 
and nicotine calculated from human liver microsomal data (Table 11).  
 
CLint, in vitro 
high-affinity 
componenta 
µl/min/mg 
CLint, in vitro 
low-affinity 
componentb 
µl/min/mg 
ΣCLint, in vitro 
 
 
µl/min/mg 
CLH, gluc 
(predicted) 
 
ml/min/kg 
CLin vivo 
(observed) 
 
ml/min/kg 
   
Dexmedetomidine  25c 2.9 (24%d) 12.5e 
DG1  17 1.2    
DG2  6.8 0.20    
Nicotine 0.88  0.88 0.67 (5%) 14.5f 
aVmax1/Km1 for reactions obeying biphasic kinetics and Vmax/Km for reactions obeying Michaelis-Menten 
kinetics 
bVmax2/Km2 for reactions obeying biphasic kinetics 
csum of  CLint, in vitro for the high- and low-affinity formations of DG1 and DG2 
d % of the observed clearance 
eIn vivo CL of dexmedetomidine in human plasma after intravenous administration was 9.0 ml/min/kg (data 
in file). CL in blood was calculated by dividing plasma clearance with RB (Table 9). 
fIn vivo CL of nicotine in human plasma after intravenous administration was approximately 14.5 ml/min/kg 
(Hukkanen et al., 2005). CL in blood was calculated by dividing plasma clearance with RB (Table 9). 
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6. Discussion 
6.1 Methods developed for the detection of N-glucuronides 
4-Arylalkyl-1H-imidazoles glucuronides were analyzed by LC using flow scintillation 
analyzer in series with a UV detector (Table 7). The reasons leading to the development of 
this particular method were severalfold. Firstly, authentic glucuronide standards were not 
available, and therefore, the development of a universal method utilizing radiolabeled 
cofactor, 14C-UDPGA, for the detection of a number of 4-arylalkyl-1H-imidazole 
glucuronides was pursued. Furthermore, the applicability of biosynthetic approaches to 
produce the N-glucuronides was limited since sufficient amounts of these N-glucuronides 
were formed only by HLM. The formation of the two regioisomeric glucuronides from 
each substrate also complicated the purification process. During development of the 
analytical methods it was noticed that the low levels of the regioisomeric N-glucuronide 
conjugates formed in the in vitro samples could not be detected by the flow scintillation 
analyzer alone. The UV detector was therefore coupled is series with the FSA, yielding a 
better sensitivity (∼0.2-1 pmol/min/mg) (Fig. 10).  
Nicotine and cotinine glucuronides were analyzed by LC-MS using commercially 
available glucuronide standards along with the respective internal standards (Table 7). In 
previous studies, clear difficulties emerged in measuring these activities due to the 
combination of low N-glucuronidation rates of nicotine and cotinine by recombinant 
UGTs and the use of less sensitive LC-UV and LC-FSA methods (Ghosheh and Hawes, 
2002b; Nakajima et al., 2002a). Developing the LC method for these analytes proved 
challenging, as both the glucuronides and the aglycone substrates are highly polar. 
Nonetheless, using a novel column suitable for hydrophilic analytes and gradient elution, 
good retention and separation were obtained (Fig. 11). This method enabled the detection 
of low levels (<0.1 pmol/min/mg) of nicotine and cotinine glucuronides in the 
recombinant UGT samples.  
6.2 Species- and tissue-selective N-glucuronidation of 
investigated compounds 
While many primary arylamines are generally N-glucuronidated by humans and a wide 
variety of animal species (Zenser et al., 1998), the N-glucuronidation of aliphatic tertiary 
amines is mostly limited to humans (Chiu and Huskey, 1998). In the case of aromatic N-
heterocycles, however, the N-glucuronidation across species is highly compound-
dependent due to the structural diversity of this group of substances (Soars et al., 2001b; 
Kaku et al., 2004; Shiratani et al., 2008). In this study, the results of the human and animal 
liver microsome incubations indicated that the N-glucuronidation of the imidazole 
compound medetomidine is largely limited to humans (Table 10). Similarly, the N-
72 
 
 
 
 
glucuronidation of nicotine and cotinine has been previously reported to be mostly 
restricted to humans (Ghosheh and Hawes, 2002a). These results suggested that these 
substrates might be metabolized by the same, human-specific UGT.  
The N-glucuronidation of the compounds investigated was also tissue-selective. While 
HLM efficiently glucuronidated medetomidine, nicotine, and cotinine, the glucuronidation 
rates in human intestinal microsomes were <2% of the rates measured in HLM (Table 10). 
This finding strongly suggests that the human UGT enzyme responsible for the 
glucuronidation of these compounds is highly expressed in the human liver, but not in the 
intestine. 
6.3 Role of human UGT2B10 in catalyzing N-glucuronidation 
Four human UGTs catalyzed the N-glucuronidation of the compounds studied. The initial 
screens indicated that the contribution of UGT1A3 and UGT2B7 to these reactions is not 
significant, while the contributions of UGT1A4 and particularly UGT2B10 are 
fundamental (Fig. 13).   
Evidence that UGT2B10 plays a major role in the N-glucuronidation of the studied 
compounds, including nicotine, cotinine, and dex- and levomedetomidine, was supported 
by several findings. Firstly, the activity assays of recombinant UGTs clearly demonstrated 
that the normalized activity of UGT2B10 towards these compounds is much higher than 
the activity of any other enzyme, including UGT1A4 (Fig. 13). Only in the case of 
dexmedetomidine was the normalized activity of UGT1A4 higher than that of UGT2B10. 
Secondly, kinetic analyses revealed that the kinetics of UGT2B10 towards these substrates 
highly resembled the kinetics observed in HLM (Tables 11 and 12). UGT2B10 and HLM 
catalyzed the N-glucuronidation of dex- and levomedetomidine at high affinities, the 
estimated Km values ranging between 7 µM and 16 µM, while nicotine and cotinine were 
lower affinity substrates. The UGT1A4-catalyzed reactions generally showed markedly 
lower affinities. Furthermore, the regioselectivity of UGT2B10 in dex- and 
levomedetomidine N-glucuronidation highly resembled the regioselectivity observed in 
HLM (Figs. 17 and 18). Finally, the measured mRNA levels in human tissues, although 
not a direct measure for the protein levels of the UGTs, suggested that the amount of 
UGT2B10 in the liver is considerable and in the same range as UGT1A4, if not higher 
(Fig. 14). Moreover, UGT2B10 was not expressed in the human intestine, which is in 
accordance with the finding that the compounds studied were very poorly glucuronidated 
by HIM (Table 10). Taken together, these results highlight the importance of UGT2B10 in 
the N-glucuronidation of these four substrates in the human liver.  
The finding that UGT2B10 catalyzes nicotine and cotinine N-glucuronidation was 
made simultaneously by our laboratory (III) and by Chen and coworkers (2007). 
UGT2B10 was found to be responsible also for the N-glucuronidation of some 
carcinogenic tobacco-specific nitrosamines such as 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL) (Chen et al., 2008b), suggesting that this enzyme plays an important 
role in the detoxification of some harmful chemicals. A functional single-nucleotide 
73 
 
 
 
 
polymorphism, UGT2B1067Tyr variant, was reported to be related to reduced N-
glucuronidation rates by HLM (Chen et al., 2008a), indicating that polymorphism of this 
enzyme may result in interindividual variation in the glucuronidation of UGT2B10 
substrates.  
6.4 Regio- and stereoselective N-glucuronidation of 
medetomidine  
N-Glucuronidation of both dex- and levomedetomidine produced two regioisomeric 
glucuronides, at N3 and N1 of the imidazole ring. Structural characterization by NMR 
revealed that DG1 and LG1, the prevailing dex- and levomedetomidine glucuronides, 
respectively, are both conjugated at N3 (Fig. 9). N-Glucuronidation of levomedetomidine 
by HLM and the major UGT enzyme 2B10 was highly regioselective, producing almost 
exclusively LG1, while dexmedetomidine glucuronidation by HLM yielded also DG2 
(∼20%), the N1-glucuronide, along with DG1. 
Kinetic analyses showed that the N-glucuronidation of medetomidine was also 
stereoselective. While the affinities of the UGT enzymes toward both enantiomers were 
comparable with the high affinity of UGT2B10 and a lower affinity of UGT1A4 (Table 
12), the stereoselectivity mainly originated from the highly different turnover rates. 
Whereas UGT2B10 catalyzed levomedetomidine glucuronidation at a superior normalized 
rate relative to dexmedetomidine, UGT1A4 was more active towards dexmedetomidine. 
6.5 In vivo relevance of in vitro N-glucuronidation assays 
The goals here were to evaluate, using different in vitro techniques, the interspecies 
differences in N-glucuronidation and to elucidate which human UGT enzymes catalyze 
these reactions. The results demonstrated that the N-glucuronidation of the 4-arylalkyl-1H-
imidazoles investigated was largely limited to humans, while the human-specific N-
glucuronidation of nicotine and cotinine has been reported earlier (Ghosheh and Hawes, 
2002a; Kuehl and Murphy, 2003). IVIVS of human liver microsomal data was performed 
to estimate the role of glucuronidation in the hepatic elimination of dexmedetomidine and 
nicotine (Table 13). The accuracy of the predictions indicated that this type of kinetic data 
can be used also for scaling purposes. Expression-normalized glucuronidation rates and 
kinetic characterization were found to be important tools in interpreting the results of 
recombinant human UGT experiments. Based on these assays, UGT2B10 was shown to be 
mainly responsible for the N-glucuronidation of medetomidine enantiomers, nicotine, and 
cotinine in the human liver, while the role of UGT1A4 was less important. It is tempting 
to speculate that UGT2B10 is also responsible for the glucuronidation of a wide variety of 
other nitrogen-containing drugs and xenobiotics. UGT2B10 may overall play a role in the 
human-specificity of many N-glucuronidation reactions.  
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7. Conclusions 
1. LC-UV combined with radioisotope detection and LC-MS methods were developed to 
analyze N-glucuronide conjugates from different in vitro samples, including human 
and animal liver microsomes and recombinant human UGTs (I, III, IV).  
2. N-Glucuronidation of medetomidine enantiomers was shown to be largely restricted to 
the human liver, while the glucuronidation activities measured in the human intestine 
and in the rat, mouse, guinea-pig, rabbit, dog, mini-pig, and monkey liver were rather 
low or below detection limits (IV). 
3. Human UGT2B10 was found to catalyze different N-glucuronidation reactions in the 
human liver. This previously little-studied enzyme turned out to be the predominant 
UGT enzyme catalyzing the N-glucuronidation of nicotine and its major metabolite 
cotinine (III).  
4. In addition, UGT2B10 was shown to be a major contributor to the N-glucuronidation 
of dex- and levomedetomidine in the human liver (IV). 
5. Recombinant UGT2B10 enzyme produced in baculovirus-infected insect cells loses 
activity during the isolation of microsomal membranes and during freeze-thaw 
cycling. The use of freshly prepared cell homogenates, when possible, is thus 
recommended (III, IV). 
6. N-Glucuronidation of medetomidine was observed to be highly regio- and 
stereospecific. In the human liver and in human recombinant UGT2B10, both 
medetomidine enantiomers are conjugated mainly at the N3 of the imidazole ring (IV). 
7. Regio- and stereospecific N-glucuronidation of medetomidine was explained by 
complex kinetics observed in human UGT1A4 and UGT2B10. UGT2B10 was found 
to be a high-affinity (low Km) enzyme towards medetomidine, while affinity of 
UGT1A4 was considerably lower (IV). 
8. The results indicate the potential importance of human UGT2B10, along with 
UGT1A4, in the hepatic glucuronidation of various nitrogen-containing drugs and 
xenobiotics.  
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